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DEDICATION 
I am dedicating this dissertation to all the "individuals" who give 
without thought. It is because of them that I truly can be considered 
"gifted". For it is due to the many unselfish acts, which I often did 
not deserve or recognize, that this work is now complete. May the road 
rise to meet you...! 
- You have to go fetch the future, it is not coming toward you, it 
is running away -
Zulu Proverb 
1 
GENERAL INTRODUCTION 
Explanation of Dissertation Format 
This dissertation Is presented In the alternate thesis format and 
Includes three sections. The paper In Section I deals with the effect 
of chelator treatment on the ability of rat Intestinal 1,25-dlhydroxy-
vitamln D receptor to bind to DNA-cellulose. The paper in Section II 
demonstrates that the rat osteosarcoma cell line 17/2.8 expresses both 
the cellular retlnolc acid binding protein and two forms of the nuclear 
retinolc acid receptor. Section III consists primarily of data 
demonstrating primarily the regulation of retinolc acid receptor 
expression in the rat osteosarcoma cells. Each section contains a 
separate list of literature cited. A brief review of the literature is 
included and describes, firstly, the molecular, biochemical and 
physical characteristics of the DNA-bindlng domain of the steroid 
hormone receptors and, secondly, the discovery, expression, regulation 
and Interaction of the retinolc acid receptors. A general Summary and 
Discussion section follows the final manuscript. 
The doctoral candidate, Kevin Brady Atkins, was the principal inves­
tigator in each of the studies. 
2 
The DNA-Binding Domain of the Steroid Receptors 
The mechanism of protein binding to nucleic acids is fundamental to 
the process of regulated gene expression. Protein-DNA Interaction 
requires compatible conformations within the protein that take advan­
tage of the repeat structure of DNA. The protein must not only be able 
to recognize discrete sequences of DNA but must also be able to bind to 
them. This recognition and binding would suggest that proteins that 
bind DNA have repeat amino acid sequences and/or can fold into an 
appropriate conformation to facilitate interaction with DNA. The 
discovery that the Xenopus transcription factor IIA (TFIIA) contains 
tandem sequence repeats of conserved cysteine and hlstldine residues 
associated with Zn atoms and the subsequent cloning of other gene regu­
latory proteins with similar cysteine containing sequences suggested a 
common structural motif. This structural unit generally is termed the 
"Zn finger." There has been some debate over which amino acid se­
quences should be called true Zn fingers and which should not (Frankel 
and Pabo, 1988; Freedman et al., 1988). That debate is technical and 
is not germane to this review. The term Zn finger therefore will be 
used to denote actual or putative domains, which have conserved cys­
teines that are necessary for DNA recognition and that have been shown 
or suggested to bind Zn. 
Zinc finger proteins have been reviewed extensively (Berg, 1986a, 
1986b, 1990a. 1990b; Evans and Hollenberg, 1988; Schlelf, 1988; Klug 
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and Rhodes, 1987; and ref. therein). This review will cover only those 
points relating to the DNÀ binding domain of the steroid/thyroid recep­
tor superfamily of proteins. 
Early biochemical analysis had established that the receptors for 
the steroid hormones and the active form of vitamin D were able to bind 
DNA (Walters, 1985; Muldoon, 1980). The nature of this interaction was 
suggested by the cloning of the human glucocorticoid receptor (GR; 
Weinberger et al, 1985). The receptor has a cysteine-rich region that 
is similar, but not identical, to other gene regulatory proteins like 
TFIIA. Overall, sequence similarities between the GR and other, subse­
quently cloned, members of this family of proteins indicate that they 
share common structural characteristics. A comparison of amino acid 
sequence homology between these receptors allowed for the division of 
the protein sequence into domains that have been labeled A, B, C, D, E 
and F. Many of these domains now have been shown to have discrete 
functional characteristics and have been reviewed extensively 
(Miesfeld, 1989; and refs. therein). Domain C is the cysteine-rich 
region, and there is a remarkable degree of homology exhibited between 
members of this family for this domain (Davis and Rushmere, 1988). In 
fact, this high degree of homology was taken advantage of in the search 
for, and discovery of, other members of this family of proteins (Arriza 
et al., 1987; Giguere et al., 1987; Petkovich et al., 1987; Mangelsdorf 
et al., 1990). 
The fact that these receptors recognize specific cis-elements 
of DNA, termed hormone responsive elements (HRE), allowed for the iden-
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tlflcation, dissection and characterization of this domain. Molecular 
manipulations of this putative DNA binding domain have confirmed that 
this region is responsible for ligand-dependent and ligand-Independent 
binding to nuclear components/DNÂ. Experiments with deletion mutants 
of estrogen receptor (ER), transiently transfected in HeLa cells, demon­
strated that those constructs that, either In whole or in part, con­
tained deletions in region C abolished tight association with the 
nucleus, independent of the presence of or the ability to bind estrogen 
(Kumar et al., 1986). Similarly, the binding of GR fragments to spe­
cific DNA sequences (glucocorticoid response element; GRE) showed that 
those fragments that included the C domain were able to bind GRE as 
efficiently and selectively as intact GR, whereas those fragments lack­
ing this domain had lost all binding activity (Rusconi and Yamamoto, 
1987). Bacterlally expressed fusion proteins, containing the C domain 
of progesterone receptor (PR), were able to retard GRE/PRE complexes by 
using gel retardation analysis (Earl et al., 1989). Insertion muta­
tions within the C domain of GR, while without effect on ligand bind­
ing, completely abolished GR induction of a reporter construct contain­
ing the GRE (Giguere et al., 1986). Deletion mutants of ER lacking 
region C were, likewise, unable to activate gene transcription from an 
estrogen response element (ERE)-linked promoter (Kumar et al., 1987). 
Analysis of the genomic organization of the genes for several 
members of this family provided Information that further ellucidates 
the structural and functional character of this domain. This analysis 
demonstrated that this domain could be divided further into subreglons 
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(CI and CII) based on the finding that the C domain Is encoded by two 
exons In the genes for GR (Weinberger et al., 1985), ER (Pongllklt-
mongkol et al., 1988), PR (Huckaby et al., 1987), mineralocortlcold 
receptor (MR; Arrlza et al., 1987) and the 1,25-dlhydroxyvitamin D 
receptor (VDR; Hughes et al., 1988). The fact that each of these exons 
separately coded for each of the putative zinc finger subdomains (CI 
and CII) further supports the critical requirements for them in 
recognition of and interactions with specific DNA sequences. 
The findings that region C is required for specific recognition and 
DNA binding and gene activation and the fact that the putative zinc 
finger subdomains are encoded by separate exons suggests yet another 
level of specificity. This suggestion was supported by additional 
molecular manipulations. Expressed ER, which have had domain C re­
placed by that domain from GR, were no longer capable of inducing -
ligand-dependent activation of an ERE-linked reporter gene construct 
(Green and Ghambon, 1987; 1989). They, however, were able to activate 
an MMTV-linked (GRE) promoter in an estrogen-dependent manner. Similar 
experiments replacing the C domain of the retinoic acid receptor (RAR) 
with that of the ER (Petkovlch et al., 1987) or GR (Giguere et al., 
1987) showed that retinoic acid binding to these chimeras stimulated 
the activity of ERE and MMTV-linked reporter genes, respectively. 
Further evidence that these putative zinc finger subdomains are 
involved in sequence recognition and binding was demonstrated by using 
chimeras in which the subdomains were replaced individually by the 
corresponding subdomaln from another receptor type (Green and Chambon, 
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1989; Green et al., 1988). In these experiments, the parent receptor 
was ER in which CI or CII was replaced by those of GR. The ability of 
these constructs to activate gene transcription through the cognate HRE 
was measured. When CI-ER was replaced by CI-GR, giving a chimera of 
CI-GR/CII-ER, there was an estrogen-dependent stimulation of activity 
through a GRE-, but not an ERE-linked construct (Green and Ghambon, 
1989). Conversely, a CI-ER/CII GR was able to stimulate estro­
gen-dependent activity from the ERE-linked promoter but not the GRE 
promoter. Similar results were obtained with GR. Additionally, dele­
tion of either subdomain of ER abolished not only transcriptional acti­
vation but also binding to cognate sequences (Green et al., 1988). 
The final molecular evidence of the importance of this region, in 
general, and the conserved cysteine containing zinc finger subdomains 
in particular was provided by site-directed mutagenesis. In a series 
of experiments, wherein most of the C domain cysteines were individu­
ally replaced by serine or alanine residues, which are of similar size 
but are unable to efficiently bind metal ions, there was a 
site-dependent loss in measured biological activity (Severne et al., 
1988). The replacement of two of the conserved cysteines within the CI 
subdomain of ER prevented activation of gene transcription (Green and 
Ghambon, 1987) . Similarly, employment of random mutagenesis of GR 
further confirmed the role of the conserved cysteine residues in acti­
vating gene transcription from GRE-linked promoters. In each of the 
cases involving a replacement of one of the conserved cysteines be­
lieved to coordinate zinc (Severne et al., 1988), there was a loss or 
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severe dlmlnlshment of gene transcription (Schena et al., 1989). Seven 
of the 12 amino acid replacements within the C domain that decreased or 
eliminated transcriptional activity involved cysteine residues. 
Biochemical and physical analysis has demonstrated that metal ions 
are required for proper folding and DNA binding of steroid receptors. 
O . 
It was shown that Zn increased the binding of androgen receptor 
(AR) to isolated rat prostate Dunning tumor nuclei (Colvard and Wilson, 
1984). This effect of zinc seemed to be selective as other divalent 
cations (Ca^"^, Mg^"*", Mn^"*", Co^"^, Cn^"*" or Cd^"*") had essen­
tially no effect. When PR preparations were treated with the chelator 
o-phenanthroline, binding of PR to purified oviduct nuclei was almost 
abolished (Lohmar and Toft, 1975). Similar experiments demonstrated 
that o-phenanthroline was effective in limiting ER binding to 
DNA-cellulose to less than 15% of control binding (Gschwendt and 
Kittstein, 1983). More extensive experiments on the effect of 
o-phenanthroline on ER and GR DNA binding support these findings. 
O-phenanthroline was able to inhibit ER binding by 71% (Sabbah et al., 
1987) and GR binding by 60% (Schmidt et al., 1981). In both cases, the 
nonchelating analog 1,7-phenanthroline was ineffective at inhibiting 
DNA-cellulose binding (Sabbah et al,, 1987; Schmidt et al., 1981). The 
addition of Zn^+ and Cd^+ (ER) and Zn^+, Co^+, and Ni^+ (GR), 
simultaneously with the chelator showed an attenuation of the inhibi­
tion. Other cations (Ca^"^, Ba^"*", Mg^"^) were without effect on 
the chelator-induced inhibition. Gel filtration or dialysis to remove 
o-phenanthroline did not reverse the inhibition, suggesting that the 
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chelator Irreversibly binds cation(s) required for receptor binding 
(Sabbah et al., 1987; Schmidt et al., 1981). The chelator EDTA, like­
wise has been shown effective, albeit less so, in inhibiting 
DNA-cellulose binding of ER (Sabbah et al., 1987), GR (Schmidt et al., 
1981) and VDR (Yamaoka et al., 1986). 
Estrogen receptors analyzed by immobilized Zn^^ affinity chroma­
tography showed that the receptor interaction was eliminated after the 
C domain had been removed tryptically (Hutchins et al., 1989). In 
addition, use of chemically synthesized peptides that correspond to CI 
n 1 
and CII of GR indicate that 1 mol of Zn was bound by each mole of 
peptide and that 90% of the metal could be removed by dialysis against 
EDTA (Archer et al., 1990). An 150-amino acid C domain-containing 
9 • fragment of GR was shown to bind two Zn atoms per molecule and is 
able to bind GRE. Dialysis against EDTA yielded an apoprotein that was 
unable to bind GRE. Target DNA binding was recovered if the apoprotein 
was pre-incubated with Zn^"*" or Cd^^ (Freedman et al., 1988). 
Finally, two-dimensional NMR demonstrated that ER is folded 
into a pair of perpendicular helical loop structures and that a zinc 
atom, coordinated by four conserved cysteines, holds the base of each 
loop (Schwabe et al., 1990). By using extended X-ray absorption-fine 
structure analysis, it was observed that the 150-amino acid C domain-
O 1 
containing GR fragment coordinated each of the two Zn atoms by a 
tetrahedral arrangement of cysteine sulfur atoms (Freedman et al., 
1988). 
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The Nuclear Receptors for Retlnolc Acid 
The action and effects of the retinoids in many tissues, organs and 
cell types have been reviewed extensively (Roberts and Sporn, 1984; 
Kamm et al., 1984; Moon and Itri, 1984; Dennert, 1984; Peck, 1984; and 
refs. therein). The mechanism of action of the retinoids, on the other 
hand, has not been established clearly. The discovery of a cellular 
binding protein for retinol (CRBP) and retinoic acid (CRABP), hinted 
that these proteins must be involved in mediating retinoid activity in 
responsive tissues or cell types (Chytil and Ong, 1984). This sugges­
tion of function was supported by the finding that CRBP (Takase et al., 
1979; Liau et al., 1981) and CRABP (Takase et al., 1986) were required 
for the uptake of their respective ligands by nuclei. It was postu­
lated, based on the data reported (Takase et al., 1979; Liau et al., 
1981; Takase et al., 1986), that CRBP and CRABP mediated the effects of 
these respective ligands at the genomic level through a mechanism analo­
gous to that proposed for steroid hormones (i.e., ligand binding to a 
receptor activates binding of the ligand/receptor complex to chroma­
tin) . Although this was an attractive model, the details have never 
been elucidated fully. One major flaw in this model stems from the 
fact that some cell types and tissues responsive to retinoic acid (RA) 
have undetectable CRABP (Chytil and Ong, 1982; Ueda et al., 1985; 
Eskild et al., 1991; Dollé et al., 1990). A major step in understand­
ing the mode of action of retinoids, especially RA, was advanced with 
the discovery of nuclear receptors for RA that belong to the 
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steroid/thyroid hormone superfamlly of llgand-modulated transcription 
factors. 
Early evidence suggested an RA-binding protein in nuclei that is 
distinct from CRAfiP. Rat testis nuclei were able to take up specifi­
cally RA from an ElA-CRABP complex without retaining CRABF (Takase et 
al., 1986). Others confirmed, by discrimination among ligands, that 
there is indeed a difference between the cytosolic and nuclear compo­
nent (Boyd et al., 1985). More recently, a RA-binding component 
extracted from nuclei of F9 murine-embryonal-carcinoma cells was esti­
mated to have an apparent sedimentation coefficient of 4.0 S (Daly 
and Redfern, 1987). This value is distinct from that for CRABP (2.0 
S), and Daly and Redfern (1987) were able to eliminate the possibil­
ity of contamination by serum albumin. These data, however, did not 
clearly establish the presence of a nuclear receptor for RA. 
Utilizing the fact that there is a great deal of homology within 
the DNA binding domain of the steroid receptors, synthetic consensus 
oligonucleotide probes were used to screen cDNA libraries (Giguere et 
al., 1987; Petkovich et al.; 1987). Positive clones were obtained and 
sequenced. The deduced protein sequence is a 462 amino acid polypep­
tide with similarities to the ligand-binding and DNA-binding domain of 
the steroid receptors (Giguere et al., 1987). Protein expressed from a 
full length clone was shown to bind RA with high affinity (Petkovich et 
al., 1987). Furthermore, it was established that this protein could 
activate gene transcription from a reporter construct in a RA-dependent 
manner (Giguere et al., 1987; Petkovich et al., 1987). Briefly, the 
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putative DNA binding domain of the newly Identified protein (RARa) 
was replaced by the DNA-binding domain of the GR (Petkovich et al., 
1987) or ER (Giguere et al., 1987). These constructs were able to 
activate transcription from either a GRE- or ERE-heterologous promoter 
linked to a reporter gene. 
Subsequently, additional receptors for ElA -- RARj9 (Brand et 
al., 1988; Benbrook et al., 1988), RAR-y (Krust et al., 1989; Zelent 
et al., 1989), RARg (in newt; Giguere et al., 1989; Ragsdale et 
al., 1989) and possibly RXRo and RXR/fl (Mangelsdorf et al., 
1990) -- have been demonstrated. In addition, it has been demonstrated 
that seven isoforms exist for RAR-y (Giguere et al. , 1990; Kastner 
et al., 1990). These isoforms are generated by alternative splicing of 
at least seven exons to give receptors that differ in the amino termi­
nus (Kastner et al., 1990). Although these receptors (i.e., a, 
P and 7) are closely homologous (e.g., 95% and 85% identity in 
DNA- and ligand-binding domains, respectively), it should be noted that 
there is a greater conservation within a subtype across species (98% 
identity for domains A, D and F) than there is between subtypes within 
a given species (Krust et al., 1989; Zelent et al., 1989). This 
observation suggests that each subtype plays a different role in regu­
lating retinoid responsive functions. 
Very little biochemical analysis has been done compared with the 
volume of work available describing other members of this family. 
Deduced amino acid sequences indicate that these retinoid receptors 
exhibit the domain structure associated with steroid receptors. The 
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estimated molecular weight of ca. 50 kDa has been confirmed by Western 
blots by using antibodies generated against human RARa and RAR/9 
(Gaub et al., 1989) and by high-performance size exclusion chromatog­
raphy (HPSEC; Nervi et al., 1989). A previous estimate of 95 kDa by 
HFSEC may represent dimers (Hashimoto et al., 1988). Immunocytochem-
ical analysis of the promyelocytic HL-60 cells resulted in a nuclear 
staining (Gaub et al., 1989). Similarly, differential fractionation of 
HL-60 cells indicates that between 80% (Hashimoto et al., 1988) and 95% 
(Nervi et al., 1989) of the RA, specifically bound to RAR, was 
nuclearly located. 
Iso-electric focusing of RAR from chick skin and HL-60 cells re­
veals an iso-electric pH of 7.5 (Saul et al., 1990). It was shown 
further that pronase was able to completely digest the RA-RAR complex, 
thus establishing its protein character. RNase showed little activity, 
whereas DNase was able to digest 29-35% of the complex. The authors, 
however, were unable to exclude the possibility of protease contamina­
tion of the DNase (Saul et al., 1990). 
Binding affinity and characteristics of RAR have been investigated 
extensively. Treatment of RAR preparations with p-chloromercuric-
phenyl sulfuric acid caused almost complete inhibition of binding (Saul 
et al., 1990). This is compared with the requirement for thiol func­
tion in ligand binding by other steroid receptors (Walters, 1985; Mul-
doon, 1980) and CRABP (Chytil and Ong, 1984). Binding of RA by RAR has 
been demonstrated to be saturable with approximately 1500 sites per 
cell (Nervi et al., 1989; Hashimoto et al., 1988). Estimates of equi-
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llbrlum dissociation constants were calculated at 0.24 nM (Hashimoto et 
al., 1988), 0.46 nM (Nervi et al., 1989) and 15 nM (Cavey et al., 
1990). It had been suggested, based on the stimulation of the activity 
of a reporter construct by RAR-ER chimeras, that RÂR/9 had a 10-fold 
greatet affinity for RA than does RARa (Brand et al., 1988). 
Others have shown a 6-fold greater affinity for RA by RAR)9 relative 
to ElARa by using a similar assay technique and using full length 
normal RAR co-expressed with reporter constructs (Astrom et al., 
1990). On the other hand, it has been reported that HL-60 native 
RARa binds RA with greater affinity than does native RAR0 
(Hashimoto et al., 1990) and that recombinant ligand binding domains 
(no differences were seen between full length and truncated forms) of 
RARa and ElAR^ had equal affinity for ElA (Crettaz et al. , 
1990). The specificity for other analogs (both natural and synthetic) 
has been investigated. In general, there are random differences in the 
binding of these analogs by RARa and RAR/9. There does seem, 
however, to be an absolute requirement for a free carboxyl end group 
(Saui et al., 1990; Crettaz et al., 1990). There is, likewise, albeit 
an incomplete one, a strong correlation between binding affinity and 
biological and transcriptional activity (Nervi et al., 1989; Saui et 
al., 1990; Astrom et al., 1990; Crettaz et al., 1990). 
Many cell and tissue types have been screened for expression of one 
or all forms (i.e., o, yS and 7) of RAR. It is not within 
the scope of this review to catalog them. There are, however, some 
observations that can be made. For RARa, there are at least two 
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transcripts of ca. 2.8 kb and 3.5 kb that are ubiquitously found in 
cells and tissues (Giguere et al., 1987; Petkovich et al., 1987; Dollé 
et al., 1990; Nervi et al., 1989; Rees et al., 1989; de Thé et al., 
1989; and refs. therein). There have been reports of an additional 
transcript in acute promyeloytic leukemia cells (ca. 4.3 kb) that have 
the t(15; 17) translocation (de Thé et al., 1990; Miller et al., 1990) 
and in a mutant P19 cell-line (ca. 2.1 kb; Pratt et al., 1990). There 
are cell and tissue-specific differences in the concentrations at which 
either transcript (2.8 kb and 3.5 kb) is found (Rees et al., 1989; de 
Thé et al., 1989). As is the case for RARjS, which also has two 
transcripts, it is as yet unclear how these transcripts are generated 
and what function they are likely to perform. 
As stated, RARj9 has two transcripts (ca. 3.1 kb and 3.4 kb) 
found either singly or together in many tissues. There are, however, a 
number of cells and tissues that do not constitutively express 
RAR)9. Notable among these are HL-60 cells (Nervi et al., 1989), 
rat placenta, ovary; testes, duodenum (Rees et al., 1989) and rat skin 
(Rees and Redfern, 1989); mouse thyroid gland, liver, gonad, skin, 
heart (Dollé et al., 1990); and human testes and breast (de Thé et al., 
1989). 
RAR-y is reported to express one transcript of ca. 2.7 kb (Dollé 
et al., 1990; Krust et al., 1989; Zelent et al., 1989; Dollé et al., 
1989; Osumi-Yamashuta et al. , 1990). To date, RAR-y has been found 
in skin (Krust et al., 1989; Zelent et al., 1989) and mesenchyme that 
differentiates to cartilage and bone (Dollé et al., 1990; Dollé et al.. 
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1989; Osumi-Yamashuta et al., 1990). In some embryonal carcinoma 
cells, probes for several of the 7-isoforms indicate the presence 
of additional and unique transcripts that were suggested to be splicing 
Intermediates (Kastner et al., 1990). 
RAR are also spatially and temporily distributed in developing and 
regenerating tissues. The details of this analysis is beyond the scope 
of this review and has been studied extensively (Eskild et al., 1991; 
Dollé et al., 1990; Giguere et al., 1989; Dollé et al., 1989; Noji et 
al., 1989; Ruberte et al., 1990). One main point, however, must be 
made. Retinoic acid forms a concentration gradient across the develop­
ing chick limb bud (Thaller and Eichele, 1987) and, therefore, has been 
identified as a morphogen. There, however, has not been shown to be a 
gradient of receptor expression across any of the developing tissues 
studied. Whereas CRABF (Dollé et al., 1989) does form a differential 
gradient across developing murine limbs, RARa is evenly distributed 
and RAR^ and RAR7 are exclusively and temporily expressed 
(Dollé et al., 1990; Dollé et al., 1989; Ruberte et al., 1990). Thus, 
it has been suggested that RA-mediated development is controlled by 
differential activation of RAR rather than differential expression of 
RAR genes (Giguere et al., 1989). 
A number of studies using cultured cells indicate that RAR expres­
sion is controlled in part by its cognate ligand, RA. In human promye-
locytic leukemia HL-60 cells (Kizaki et al., 1990; Gallagher et al., 
1989) and hematopoietic cells blocked at different stages of differenti­
ation (Kizaki et al., 1990), RA (at 10"® M for up to 96 h [Gallagher 
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et al., 1989] or 10'® M for 24 h [Kizakl et al., 1990]) had no effect 
on the steady state concentrations of mHNÂ for RARa. Others re­
ported a less than 2-fold Increase in RARa mRNÂ from HL-60 cells 
during RA (5 x 10"^ M) Induction for 24 h (Song and Siu, 1989). The 
same authors (Song and Siu, 1989) reported an 8-fold increase in 
RARa mRNA at 2 h of treatment (5 x 10"^ M RA) in the embryonal 
carcinoma P19 cells. There was a slower (12 h) 7-fold induction of 
RARa mRNA in the RA nonresponsive mutant RAC65 cells derived from 
P19 cells with an additional predominant transcript of 2.1 kb (Song and 
Siu, 1989). When vitamin A-deficient rats were injected with retinol, 
there was a 2.5-fold increase in rat testis RARa mRNA within 30 
min, which peaked at 3-fold and remained at that level for 7 h and 
declined thereafter to control level at 12 h (Kim and Griswold, 1990). 
Treatment of the melanoma S91 cell line with 10'® M RA for 24 h is 
either without effect (Redfern et al., 1990) or increases RARa mRAR 
1.5-2-fold (Clifford et al., 1990). 
The regulation of RAR/9 by RA is generally more marked. The S91 
melanoma cells, which do not constitutively express RAR/9, respond 
to RA by inducing mRNA to a high level at 2-4 h, which peaks at 24 h 
post-treatment (Redfern et al., 1990; Clifford et al., 1990). The 
teratocarcinoma F9 cells respond to 10"^ M RA by increasing tran­
scripts for RAR)3 within 3-12 h and reached a peak of 20-30 fold 
increase by 24 h (Hu and Gudas, 1990; Martin et al., 1990). This RA 
induction was abrogated by the transcription inhibitor actinomycin D 
(Hu and Gudas, 1990) and was inhibited by cyclic AMP analogs, which had 
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no effect in the absence of RA (Hu and Gudas, 1990; Martin et al., 
1990). The cyclic AMP analogs, in the presence of RA, which had little 
or no effect by itself, also decreased the concentrations of mRNA for 
RARa and RAR-y (Hu and Gudas, 1990). Analysis of the effect of 
10"® M RA treatment on RAR/S mRNA levels in hepatoma PLC/PRF/5 and 
HEPG2 cells showed a rapid accumulation, increasing to 10- to 50-fold 
above control (de Thé et al., 1989). In addition, this increase was 
inhibited by actinomycin D and was shown to be caused, in part, by 
increased transcription (de Thé et al., 1989). 
In the few cases (Kastner et al., 1990; Redfern et al., 1990; Clif­
ford et al., 1990; Hu and Gudas, 1990; Elder et al., 1990) where concen­
trations of RNA for RAR-y have been measured, RA treatment has been 
without effect. 
In general, RA homologously regulates only RAR/9. There is a 
small effect on RARa, but this is found in only a few cases, 
whereas the effect on RAR/9 by RA is relatively large and nearly 
universal. This result is supported by the finding that the promoter 
region of the human RARa gene linked to a reporter gene is not 
activated by cotransfected RARa, RAR/9 or RAR-y (Brand et 
al., 1990). The fact that RAR/9 is responsive to RA lead to the 
sequencing and characterization of the 5' flanking region of human (de 
Thé et al., 1990; Hoffmann et al., 1990) and mouse (Sucov et al., 1990) 
RARjS genes. These researchers were able to identify a tandem re­
18 
peat of a 6 bp motif (GTTCAC) which, when linked to a reporter con­
struct, confers RÂ responsiveness when cotransfected with RARa (de 
Thé et al., 1990), RAR)9 (de Thé et al, 1990; Sucov et al., 1990; 
Hoffmann et al., 1990) and RAR-y (Sucov et al., 1990). This effect 
was specific for RAR because cotransfection with the receptors for 
thyroid, estrogen, glucocorticoid and 1,25-dihydroxyvitamin D hormones 
failed to activate the reporter construct (Sucov et al., 1990; Hoffmann 
et al., 1990). It also was shown by gel retardation assay that 
RAR)9 (de Thé et al., 1990; Sucov et al., 1990; Hoffmann et al., 
1990) and RAR-y (Hoffmann et al., 1990) bind the DNA sequence with 
or without RA. It was, likewise, shown that thyroid hormone receptor 
(TR) binds to this sequence irrespective of the presence of ligand 
(Hoffmann et al., 1990). 
The binding of TR to this retinoic acid response element (RARE) is 
not unusual. Other members of this family of receptors are able to 
bind to response elements that have been identified for other family 
members. For example, progesterone receptors can bind a glucocorticoid 
response element and RAR can recognize a vitamin D response element 
(Schule et al., 1990). There are, however, some interesting 
interrelationships between RAR and TR. Chromosome mapping showed that 
RARa maps to the q21 band of chromosome 17 (Mattel et al., 1988a) 
and that RAR)9 maps to p24 of chromosome 3 (Mattel et al., 1988b). 
Interestingly, TRo and TR^ map to 17qll.2-ql2 and 3p21.33-22, 
respectively, leading to the suggestion that TR and RAR arose from a 
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common ancestoral gene. This supposition is supported by a number of 
pieces of evidence. Firstly, RAR and TR can induce or inhibit gene 
expression through a common response element (Umesono et al., 1988; 
Hudson et al., 1990). Secondly, thyroid hormone receptors can interact 
with RAR to modulate gene transcription in a positive or negative fash­
ion, depending on the presence of thyroid hormone. It was shown that 
ligand-activated RAR induced gene transcription via a thyroid hormone 
response element (TRE) linked to a reporter construct and was repressed 
by TR in the absence of its ligand, whereas there is a synergistic 
activation when both receptors and cognate ligands are present 
(Granpner et al., 1989). Further, by using the TRE/RARE portion of the 
EGF gene promoter, there was inhibition of gene transcription when 
either receptor was present individually or together in the presence of 
their cognate ligands. This inhibition could be relieved partially if 
only a single ligand was used when both receptors are present (Hudson 
et al., 1990). 
This finding is explained by the third interaction between TR and 
RAR, namely, heterodimer formation. It is well known that steroid 
hormone receptors form homodimers that bind to their respective re­
sponse elements. It was shown, on the other hand, by cross-linking of 
protein bound to a TRE from several sources that RAR and TR formed 
heterodimers (Glass et al., 1989). Additionally, RAR binding to the 
TRE exhibited remarkable cooperativity of binding in the presence of TR 
(Glass et al., 1989). These investigators were, likewise, able to 
demonstrate interaction between these receptors independent of ligand. 
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In this case, RAR in the absence of RA was able to inhibit 
ligand-activated TR induction of gene transcription (Glass et al., 
1989). This result is similar to that reported by Hudson et al. (1990) 
who suggested a competition between hormone-activated receptor and 
unliganded receptor for sequence binding or dimer formation. Support 
for the latter is suggested by research using a TR mutant that lacks 
the DNA binding domain and, hence, is transcriptionally inactive. 
These mutants were able to block transactivation by RAR (Forman et al., 
1989). It must be recalled, however, that TR and RAR are capable of 
binding response elements in the absence of ligand (Hoffmann et al., 
1990) and, therefore, competition for sequence binding also may be 
involved. 
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SECTION I 
EFFECT OF 1,10-PHENANTHROLINE ON DNA BINDING BY 
1,25-(0H)2D receptor 
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INTRODUCTION 
The active metabolite of vitamin Dj, 1,25-dihydroxyvitamin Dg 
[1,25(011)203], acts through the classical steroid, receptor-
mediated mechanism (1-3). Receptors for this seco-steroid have been 
found in a wide variety of tissues (4). Intestine is a major target 
organ for this hormone wherein the major effect is regulation of 
calcium homeostasis. Â direct correlation between occupied 
1,25-(0H2)D3 receptor (VDR) and induction of intestinal vitamin 
D-dependent calcium binding protein and elevatfed plasma Ca^^ has been 
demonstrated (5). 
When bound to the hormone, the receptor undergoes an, as yet 
unclear, "activational" process that leads to a higher affinity for 
chromatin (6). When bound to specific DNA sequences, occupied hormone 
receptors are believed to modulate the transcriptional activity of 
steroid-specific genes (7). The mechanism of this receptor/DNA 
interaction is speculative (7). 
The VDR is a member of the family of steroid/thyroid hormone 
receptor proteins. The domain structure of these proteins is such that 
there is a fairly high degree of homology between members in the 
putative DNA binding domain. Within this region are a number of 
conserved cysteines, which are intimately involved in the ability of 
these proteins to interact with DNA and regulate gene transcription 
(8-11). 
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The divalent cation Zn Is Involved In promoting the ability of 
estrogen-(12, 13), glucocorticoid (14, 15), and progesterone (16) 
receptors to Interact with DNÂ. These data are consistent with those 
for other so-called zlnc-flnger DNA binding proteins (17-21), wherein 
O . 
Zn is involved In the folding of these proteins into a functionally 
correct conformation. Treatment of receptor preparations with 
chelators of divalent cations (12-16, 22) or utilization of 
site-directed mutagenesis of putative metal binding sites (8) leads to 
defective DNA binding or receptor function. The aim of the present 
work Is to biochemically elaborate on the limited data (22) that 
implicates the VDR as a Zn^'^-dependent DNA binding protein. 
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MATERIALS AND METHODS 
Chemicals and buffers 
1,25-Dihydroxyvitamin D3 was a gift from Dr. Milan Uskokovic 
(Hoffmann-La Roche, Inc., Nutley, NJ). l,25-(OH)2[26-27-^H]D3 
(90 Ci/mmol) was prepared by reacting [ HJmethyl magnesium iodide 
with 27-nor-25-keto-l-OHD3 with purity determined by HPLC to be 
>95%. The purity and concentration of nonradioactive l,25-(OH)2D3 
were determined from the ultraviolet absorption spectrum using a molar 
extinction coefficient of 18,200 M'^ cm'^. Homogenization 
and dialysis buffers contained 50 mM Tris pH 7.4, 5 mM dithiothreitol, 
200 ng/mL soybean trypsin inhibitor, and the indicated 
concentration of KGl (KTD). The elution buffer for size exclusion HPLC 
was 20 mM sodium phosphate pH 7.4, 200 mM KCl, 2 mM dithiothreitol, 
0.1% Tween 20, and 0.5% glycerol. EDTA (Eastman, Rochester, NY) was at 
the indicated concentrations in 300 mM KTD. 1,lO-Phenanthroline 
(o-phen) (Sigma, St. Louis, MO) and 1,7-phenanthroline (ALFA, Danvers, 
MA) were made as stock solutions in ethanol and diluted to the 
indicated concentrations in 300 mM KTD; BaCl2, CaCl2, CdSO^, 
MgCl2, and ZnCl2 were at the indicated concentrations in 300 mM 
KTD. 
Aniaals and tissue preparation 
Male Holtzman rats (200-300 g) (Holtzman, Madison, WI) fed a stock 
diet (Teklad, Madison, WI) were used. Rats were decapitated after 
anesthesia with 50% CO2. The first 20 cm of intestine proximal to 
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the pylorus were removed and rinsed with Ice cold phosphate-buffered 
saline (pH 7.4). The luminal surface was exposed and the mucosa 
removed by scraping with a glass slide. All subsequent steps were at 
4*C. The mucosal scrapings were made 20% (v/v) In 500 mM KTD and 
homogenized with three 10-s bursts with a Folytron FT-10 homogenlzer 
(Brlnkman Instruments, Westbury, NY). The homogenate was centrlfuged 
at 229,000 X g for 20 mln and the resulting supernatant (cytosol) was 
used as indicated. In all cases, the unoccupied receptor was labeled 
,by Incubating for 2 hr at 4*C with 10 nM [^H]l,25-(OH)2D3 either 
alone or with a 200-fold excess radlolnert 1,25-(OH)2^3. Any 
excess unbound hormone was removed by using 1% charcoal, 0.1% dextran 
in TD buffer (50 mM Tris, 5 mM dlthlothreltol). 
Total receptor and DMA-cellulose binding aaaaj^a 
In brief, receptor assays were conducted as follows. Cytosol was 
diluted 1:1 with 300 mM KTD or the appropriate chelator (in 300 mM KTD) 
at the start of incubation with radio-label. In the cases where cation 
was added, either simultaneously or later, the chelator and cation 
solutions were added so that the final dilution was 1:1. Total bound 
hormone was determined by using hydroxyapatlte as previously described 
(23). DNA-cellulose (DNA/C) was prepared (24). DNA/C binding was 
determined by batch assay. A 150 /iL aliquot of labeled cytosol was 
added to 850 fiL of 85 mM KTD, including 550 fiL of a 50% slurry 
of DNA/C. The final volume was 1 mL, assuring a concentration of KCl 
between 140-150 mM. Binding was allowed to proceed for 45 mln with 
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fragment vortexing. After 3 washes the DNA-cellulose was eluted twice 
with ethanol. After evaporation, the eluate was counted for 
radioactivity. 
DEAE-Sephadex and size exclusion HPLC 
DEAE-Sephadex chromatography was performed as described (25). High 
performance size exclusion chromatography (HFSEC) analysis of the 
treated cytosols was performed as previously described (26) with the 
following changes; chromatography was performed with a Waters 
Associates Model ALC/GPC 204 liquid chromatograph (Waters Associates, 
Milford, MA). The column was a double Spherogel TSK SW (7.5 mm x 60 
cm) (Beckman, Palo Alto, CA) equilibrated at 4*0 with the elution 
buffer described above. A 400 fiL aliquot of radio-labeled cytosol 
was chromatographed at a flow rate of 1 mL/min. One-milliliter 
fractions were collected on an ISCO Model 568 fraction collector (ISCO, 
Lincoln, NE). A 200 nL aliquot of each fraction was taken to 
determine radioactivity as monitored by liquid scintillation 
spectrometry. [^^C]-Ovalbumin and [^^C]-gamma globulin were used 
as internal markers (Dupont/NEN, Wilmington, DE). The remainder of 
each fraction (800 /iL) was assayed for DNA/C binding by incubating 
with 1 mL of a 50% slurry of DNA/C in TD buffer. 
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RESULTS 
The effect of Increasing concentrations of EDTA and o-phen on 
receptor DNA binding was examined. There was a dose-dependent decline 
(Fig. 1) In DNA binding by VDR with Increasing o-phen concentration up 
to 3 mM. EDTA exhibited a similar response up to 1 mH, but the 
decrease in DNA binding seen at concentrations above 1 mM was more 
gradual. The addition of Increasing concentrations of the nonchelatlng 
analog of o-phen, 1,7-phenanthrollne (Fig. 1), Indicates that the 
effects of o-phen on DNA binding by VDR are not attributable to 
nonspecific hydrophobic Interactions, but rather are the result of its 
ion chelating capacity. Because 3 mM o-phen gave maximal response, 
this concentration was used for all subsequent experiments with o-phen 
and EDTA. 
We next tested the ability of several cations to block the 
chelator-mediated Inhibition of VDR binding to DNA (Fig. 2 and 3). The 
cations, Ba^*, Ca^*, or Mg^*, when added (1 mM) to cytosol 
simultaneously with chelator (3 mM), were ineffective in blocking 
chelator-mediated inhibition of VDR binding to DNA/C. When Cdf* or 
were added simultaneously with chelator, there was a marked 
attenuation of the inhibition of DNA binding of VDR caused by either 
chelator alone. Cd^* was more effective than at blocking 
inhibition. The addition of any of the cations to cytosol preparations 
pre-incubated with the chelators (Fig. 2 and 3) was not effective in 
blocking the inhibition of VDR binding to DNA. 
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To Investigate the reversibility of the chelator-mediated 
Inhibition of DNA binding, o-phen-treated cytosol was dlalyzed to 
remove the chelator. Figure 4 shows that when o-phen-treated cytosol 
was dlalyzed, DNA binding was not restored. Pre- and post-dialysis DNA 
binding activity was essentially the same for control and 
chelator-treated samples. The addition of Cd^"*" or Zn^"*", but not 
Ba^"*", Ca^"*", or Mg^^, after the removal of o-phen by dialysis was 
O É 
effective In restoring DNA binding. When Cd was added, greater. 
than 75% of the lost DNA binding activity was recovered. The addition 
of Zn was not nearly as effective, because only about 31% of the 
lost activity was recovered. 
The effect of o-phen treatment on physical characteristics of VDR 
was examined. Analysis of VDR by DEAE-Sephadex chromatography 
Indicated thab both control and o-phen-treated samples had essentially 
the same elution profile (Fig. 5).. Bound radioactivity from control 
cytosol peaked at approximately 95 mM KCl, while radioactivity from 
o-phen-treated cytosol peaked at 100 mM KCl. Although there was a 
slight difference in elution, the major difference was in recovery of 
radioactivity. The recovery of bound radioactivity for control cytosol 
(96%) was higher than for o-phen-treated cytosol (80%). This 
difference in recovery is apparently the result of a loss of ability to 
bind the resin, because no significant radioactivity was recoverable 
from either column with ethanol. 
Analysis of the HPSEC elution profile of specifically bound label 
of both control and o-phen-treated cytosols is Illustrated in Fig. 6. 
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Control samples eluted as a single peak with a retention time of 19 
min. Samples treated with o-phen eluted as two peaks, with retentions 
of 12 and 21 min. This change in elution is associated with the 
chelating activity of o-phen, because cytosol treated with 
1,7-phenanthroline had a retention time of 19 min (data not shown). 
The o-phen-treated samples to which Cd^* had been added after 
dialysis exhibited nearly the same elution profile as cytosol treated 
with o-phen alone. Interestingly, the 12-min peak was retained, 
whereas the later peak had shifted to 19 min. The radioactivity 
eluting within the early and late peaks as a percentage of the total 
radioactivity was essentially the same for o-phen cytosol (33% and 67%) 
and the dialyzed samples to which Cd^* was added (36% and 64%). 
The ability of specifically bound radioactivity from each fraction 
to bind to DNÂ was evaluated (Fig. 7). The DNA binding activity for 
control cytosol peaked at 19 min. There was DNA binding activity in 
both the 12- and 19-min peak for o-phen-treated samples. The binding 
in each peak as a percentage of the total radioactivity within each 
peak was 21.2% and 30.7% for the 12- and 19-min peak, respectively. 
The DNA binding activity for those o-phen-treated samples which were 
dialyzed and had Cd^* added peaked at 12 and 19 min also. The 
binding in each peak as a percentage of total peak radioactivity was 
32.9% and 33.3% for 12 and 19 min, respectively. 
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DISCUSSION 
The ability of many DNA binding proteins to interact with DNA with 
high affinity is dependent on the presence of a divalent cation. 
Progressive loss of ability to bind DNA/C by the rat intestinal VDR is 
dependent on the chelator and the concentration of chelator (Fig. 1). 
1,10-Phenanthroline is much more effective in inhibiting DNA binding 
than is EDTA. This inhibition by 1,10-phenanthrollne suggests that the 
ability of the VDR to bind DNA is limited by the loss of a cation that 
o-phen can chelate. Of the cations tested, EDTA has the ability to 
2+ 
chelate all of them, whereas o-phen can chelate only Zn and 
Cd^*. Additionally, o-phen can chelate Fe^* and Cu^"*", but the 
possibility that these cations are involved is remote (14, 22). 
Previous work (14) investigating direct interactions of DNA with, or 
degradation by, o-phen and its Cu^* complexes eliminated these 
possibilities as contributors to the inhibitory response of 
glucocorticoid receptor (GR). The fact that Ba^*, Ca^*, or Mg^"*" 
do not attenuate the effect of EDTA (Fig. 2) may indicate that, at the 
concentrations used, they are ineffective substitutes (I.e., cannot be 
coordinated by the receptor) for the native cation. The positive 
effect of higher concentrations of these and other cations (21), 
exclusive of Cd^* and Zn^*, is possibly because of a sparing, 
rather than substituting, for the cation associated with the receptor. 
The data (Fig. 2 and 3) for the test when Cdf* and Znf* are added 
simultaneously with either chelator suggest, In view of the lack of 
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effect of the other cations with EDTA, that and Zn^^ are not 
only sparing receptor-associated cation but may, in fact, be 
substituting for it. This supposition is supported further by the 
results of the addition of Cd^* and Zn^"*" after dialysis to remove 
excess o-phen (Fig. 4). 
Reports of the removal of o-phen by gel filtration of GR (14) or 
dialysis of estrogen receptor (ER) (13) preparations indicated that the 
receptors were still incapable of binding DNA with high affinity. It 
has been reported (15), however, that binding activity could be 
restored to GR when Cd^"*" or Zn^^ were added to receptor 
preparations from which the chelator had been removed. Our results and 
those of others (15, 27, 28) suggest the removal of an associated 
cation by the chelator and the possible formation of a DNA 
binding-defective apo-protein. Addition of the cation post-dialysis 
reconstitutes the protein and restores its ability to bind DNA. 
The mechanism whereby the chelator exerts its effect is most likely 
through the removal of cation from the receptor rather than binding to 
the metal in place. The results of DEAE chromatography (Fig. 6) show 
little or no apparent change in surface charge of VDR capable of 
binding the resin. A change in charge might be expected if a direct 
interaction between receptor and chelator occurred. Both control and 
o-phen-treated VDR elute at essentially the same KCl concentration. 
There was, however, a difference in recovery between control and 
chelator-treated cytosols. Approximately 16% less radioactivity was 
recovered when chelator-treated cytosol was chromatographed compared 
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with control cytosol. No additional radioactivity was recoverable from 
either column with the addition of ethanol. Possibly VDR, which is not 
retained by the resin, is either VDR that is no longer capable of 
binding DNA or VDR which has formed aggregates (see below). This 
suggestion, however, is speculative. 
In contrast, there was a marked change in the elution profile of GR 
treated with o-phen. Whereas control samples eluted at 0.06 M KCl, 
o-phen-treated samples eluted essentially at 0.18 M KCl. There also 
was a decreased recovery of eluted radioactivity associated with 
o-phen-treated GR samples. The radioactivity was found to be 
irreversibly bound to the resin, because as high as 2 M KCl was 
incapable of eluting the GR (14). 
The most obvious physical effect of chelator treatment (o-phen) is 
the change in retention upon HPSEC analysis (Fig. 6). Radioactivity in 
control cytosol peaked at 19 min, whereas radioactivity in 
chelator-treated cytosol had peaks of 12 and 21 min. The formation of 
apparent aggregates (12-mln peak) is similar to results (13) obtained 
on glycerol gradient analysis of transformed ER treated with 3 mM 
A , 
o-phen. The HPSEC of o-phen-treated cytosol to which Cd had been 
added after dialysis showed two peaks also. The 12-min peak was 
retained, but the second peak was at 19 min, rather than 21 min. These 
results were surprising because we initially had thought that the loss 
of DNA/C binding was associated with aggregation (12-mln peak). The 
O I 
results of the HPSEC of o-phen-treated cytosol that had Cd added to 
it after dialysis indicates that aggregation is not reversed. The 
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addition of cation after dialysis of chelation-treated samples does not 
change the relative amount of radioactivity within the 12-min peak 
compared with chelator alone. Likewise, the apparently aggregated 
receptor retains some affinity for DNÂ (Fig. 7) and the DNa/C binding 
as a percentage of the radioactivity eluting within the 12-min peak 
does not change after addition of cation after dialysis from that of 
chelator treatment alone. This observation suggests the cation effect 
after dialysis is other than to reverse aggregation. 
The results of the HPSEC of the chelator-treated cytosol (Fig. 6) 
Indicate that not only is there an aggregate formation, but there is 
also an apparent conformational change. Whereas control cytosol has a 
peak at 19 mln, the second peak for o-phen-treated cytosol is at 21 
min. This observations suggests that the receptor is probably 
smaller. Research on the effect of EDTÂ (1 mM) on chick VDR indicated 
an associated cleavage of the VDR (1). The conditions employed (37*C 
for 1 hr, or 4'C for 72 hr) were severe, and they involved no protease 
inhibitor. Similar experiments by us using rat intestinal VDR and 
trypsin inhibition (data not shown) showed no difference in either 
receptor number or DNA binding between treatments (1 mM EDTA versus 
control) at 37"C for 1 hr. On the other hand, there was greater 
receptor number and ability to bind DNÂ in the presence of EDTA 
compared with control or EDTA plus 0.3 mM Zn^* after 72 hr at 4*C. 
2+ 
The data of HPSEC of the o-phen-treated cytosols to which Cd 
was added after dialysis suggest that there is a conformational change 
O • 
rather than a reduction in size. The addition of Cd shifts the 
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elutlon of the second peak from 21 mln to 19 mln, which Is similar to 
that of the control. This shift suggests that the chelator removes 
cation from the receptor, forming apparently smaller apo-receptor which 
elutes as a peak of radioactivity at 21 mln. (The peak of DNA binding, 
however, is at 19 mln.) When Cd is added after dialysis, the 
apo-receptor coordinates the cation, forming hole-receptor, which 
elutes at 19 mln. This apparent change in conformation also is 
associated with the increased ability to bind DNA. The ratio of DNA 
binding to total receptor eluted within the 12-mln peak is similar for 
O i 
both o-phen samples and o-phen samples to which Cd was added after 
dialysis. The ratio of DNA binding to total receptor within the later 
peak is greater for the o-phen-treated samples to which Cd was 
added after dialysis than for o-phen-treated samples. It is important 
to recall that the amount of radioactivity elutlng in either the early 
or late peak is relatively the same for both treatments. Others (15, 
20) have shown it possible to reconstitute metalloproteins after 
removal of cation. Structural analysis of GR (15) indicates that 
cations (Cd^* or Zn^*) are required for proper folding of the 
molecule and leads to restoration of lost DNA binding activity. 
The data presented herein, coupled with the sequence homology of 
VDR with the other steroid receptors in the DNA binding domain, provide 
further biochemical evidence for the proposal that VDR is a 
metalloproteln. Work involving site-directed mutagenesis of the 
conserved cysteines within the DNA binding domain coupled with X-ray 
analysis will be required to provide definitive proof. 
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Figure. 1. Effect of 1,10-phenanthroline, 1,7-phenanthroline and 
EDTA on the binding of VDR to DNA-cellulose. Labeled 
cytosols were incubated at A'C for 2 h with different 
concentrations of 1,10-phenanthrollne (#), 1,7-phenan-
throline (A) and EDTA (0). VDR binding was per­
formed as described in Methods. Results are expressed 
as percent of control VDR binding. Approximately 44% 
of VDR bound DNA-cellulose 
39 
Control 
Simultaneous Post - Chelator 
Figure 2. Influence of cations on inhibition of VDR binding to 
DNA-cellulose by EDTA. Labeled cytosol was incubated 
with 3 mM EDTA (-)• Cations (1 mM) were added either 
at the beginning (simultaneous) or at the end (post-
chelator) of incubation with EDTA 
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Figure 3. Influence of cations on hibition of VDR binding to DNÂ-
cellulose by 1,10-phenanthroline. Labeled cytosol was 
incubated with 3 mM 1,10-phenanthroline (•). Cations 
(1 mM) were added either at the beginning (simultaneous) 
or at the end (post-chelator) of incubation with 
1,10-phenanthroline 
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Figure 4. Effect of dialysis on Inhibition of VDR binding to 
DNÂ-cellulose by 1,10-phenanthroline. Labeled cytosol 
either with or without 3 mM 1,10-phenanthroline (phen) 
was dialyzed against 100 vols of 400 mM KTD. After 
dialysis (post), cations (1 mM) were added to 
1,10-phenanthrollne-treated cytosol 
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Figure 5. Chromatography of VDR on DEÂE-Sephadex. Labeled 
cytosol either with (—) or without (-) 1,10-phenan-
throline was diluted 1:4 with TD buffer and loaded on 
DEAE-Sephadex. The columns were eluted in 1 mL 
fractions with a 0-400 mM KCl (-«-) gradient 
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Figure 6. High performance size exclusion chromatography of VDR. 
A 0.4 ml sample of labeled control, 3 mM 1,10-phenan-
throline-treated cytosols or a phenanthroline-treated 
sample to which Cd was added after dialysis (CD 
dialyzed) were chromatographed on a Sphenogel TSK SW 
column (7.5 mm x 60 cm at a flow rate of 1 ml/min). 
One-ml fractions were collected and a 0.2 mL aliquot 
was counted for radioactivity. Data is presented a 
specifically bound [ H]-l,25-(OH)2D3/fraction 
44 
Control 
CD DIalyied 
1,10 Phen 
Fraction 
Figure 7. DNA-cellulose binding of VDR analyzed by high 
performance size exclusion chromatography. Cytosols 
were chromatographed and 1 ml fractions collected as 
described. An 0.8 mL aliquot from each fraction was 
for DNA-cellulose binding 
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SECTION II 
EVIDENCE FOR THE PRESENCE OF A RETINOIC ACID 
RECEPTOR IN RAT OSTEOSARCOMA CELLS 
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INTRODUCTION 
Vitamin A is required for the development and maintenance of many 
tissues. Vitamin A and its analogs, such as retinoic acid (RA), are 
known to have profound effects on bone development. In vitamin A 
deficiency, bone becomes thickened and there is ectopic bone 
deposition. In the case of an excess in vitamin A, there is increased 
collagenase activity, a decrease in collagen synthesis by the 
osteoblasts, and a thinning of the bone. The evidence suggests that 
these changes are because of decreased and increased bone resorption in 
deficiency and excess, respectively (1). 
Retinoic acid is known to have equal or greater activity than 
retinol in bone. In transformed rat osteoblast-like cells, RA is 
reported to Increase the content of the nuclear receptor (VDR) for 
1,25-dihydroxyvltamin D [1,25-(OH)2D3] and decreased alkaline 
phosphatase activity (2, 3). In nontransformed osteoblast-like cells, 
RA increased VDR from mouse-derived cells, whereas it down-regulates 
VDR in rat-derived cells (4). Using rat osteosarcoma cells, RA 
treatment increases mRNA for VDR (5) and decreases mRNA for alkaline 
phosphatase (3). 
Until recently, it was believed that the effects of RA at the 
genomic level were mediated by the cellular binding protein for RA 
(CRABF), because this binding protein was necessary for saturable 
binding of RA in testicular nuclei (6). On the other hand, some cell 
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lines that are responsive to RA have been reported not to express GRABF 
(7). A crucial advancement in understanding the mechanism of RA 
activity was the discovery of multiple forms (a, and 7) 
of nuclear receptors (RAR) for RA (8-12). These nuclear receptors 
belong to the large family of ligand-responsive trans-acting factors, 
of which the steroid and thyroid hormone receptors are members. 
The rat osteosarcoma cell line ROS 17/2.8 responds to RA treatment 
as described (2, 3, 5). The cells were reported, however, not to have 
detectable GRABF (7). It was reasonable, therefore, to assume that any 
effects RA has on alkaline phosphatase and VDR gene transcription must 
be mediated by one (or all) of the forms of RAR. In the present paper, 
we have identified a high affinity RA-binding activity with 
characteristics of RAR, and have correlated this binding to VDR 
up-regulation. We, likewise, have confirmed the presence of RARa 
and by Northern analysis and have shown that ROS 17/2.8 express a 
form of GRABF. 
4 
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MATERIALS AND METHODS 
General 
Retlnolc acid analogs SRI 6409-40 and SRI 5442-60 were provided by 
M. I. Dawson (SRI International, Menlo Park, CA). The analog Ro 
13-7410 was synthesized by Hoffmann-La Roche (Nutley, NJ). All 
trans-RA and retinol were purchased from Sigma (St. Louis, MO). All 
trans-[^H]-RA (50 Ci/mmol) was purchased from Dupont/NEN (Wilmington, 
DE). 
Cell culture 
Rat osteosarcoma (ROS 17/2.8) cells were grown in RPMI 1640 
supplemented with 10% fetal calf serum (PCS) and antibiotics. Cells 
were grown to confluence (7 to 8 days) with feeding every third day at 
an incubator temperature of 37*C, an atmosphere of 5% CO^, and 
humidified air. The confluent cells were washed once in the flask with 
phosphate-buffered saline (pH 7.4) (PBS) followed by removal with 
trypsin. Following centrifugation, the cells were washed one time in 
PBS. 
Initially, cells were homogenized in a high salt buffer (500 mM 
KCl, 10 mM Tris, pH 7.4) to extract putative nuclear receptor. This 
procedure was modified after an additional RA-binding protein became 
evident. For cytosol preparation, cells were homogenized at 20 X 10® 
cells/ml of hypotonic buffer (TD) containing 10 oM Tris (pH 7.4), 5 mM 
dithiothreitol (DTT), and 200 pg/ml soybean trypsin inhibitor, 
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followed by centrlfugatlon (230,000 X g) using a Beckman Ti 70.1 rotor 
and L8-80M ultracentrifuge. To obtain a whole cell extract, cells were 
homogenized at 20 X 10® cells/ml of hypertonic buffer (KTD) 
containing 500 mM KCl, 10 mM Tris, pH 7.4, 5 mM DTT, and 200 /ig/ml 
soybean trypsin-inhibitor, and centrlfuged as above. This extract then 
was precipitated with 40% saturated ammonium sulfate. After 
centrlfugatlon, the pellet was dissolved in one-half volume KTD. 
Because this method allowed the enrichment of the RA-binding activity 
that is present in a KTD extraction of crude nuclear pellets, it is, 
therefore, identified as the nuclear fraction or extract. A 500-ml 
aliquot (triplicate) from the cytosolic and from the nuclear extract 
was labeled with [^H]-RA at 4'C for 3 h with or without a 100-fold 
excess RA at the indicated concentration. Bound and free radlolabel 
were separated by hydroxyapatite chromatography. 
Sucrose gradients 
Sucrose (5 to 20% w/v KTD) density gradient centrlfugatlon was 
performed on 200-pl labeled allquots of both cytosolic and nuclear 
extracts at 438,000 X g for 18.5 h in a Beckman SW60 Ti swinging bucket 
rotor and a Beckman L8-80M ultracentrifuge. Two-drop fractions were 
collected and counted for radioactivity in Beckman Ready SOLV HP by a 
Beckman LS-7800 liquid scintillation counter. All assays are corrected 
for nonspecific binding and are presented as specifically bound 
[^H]-RA. [^^C]-Ovalbumin and [^^C]-gamma globulin (Dupont/NEN, 
Wilmington, DE) were included as Internal markers. 
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Northern blot analysis 
Total RNÂ was extracted from cells by the acid guanidlnlum 
thiocyanate-phenol-chloroform method (13) and enriched for poly (A)+ 
RNA on an ollgo-dT-cellulose column. Ten to 20 fig of poly (A)+ 
enriched RNA was fractionated by electrophoresis on a 1% agarose/5% 
formaldehyde slab gel and transferred to Optibind nitrocellulose 
(Schleicher and Schuell, Keene, NH). The RNA was cross-linked to the 
membrane by exposure to UV light for 5 min. Membranes were 
prehybridized for 1 h at 42*C in 50% formamlde, 5X Denhardt's solution, 
0.5% sodium dodecyl sulfate (SDS), 5X SSPE (IX SSPE; .18 M NaCl, 10 mM 
NaPO^, pH 7.4, 1 mM EDTA), and 50 fig/ml sonicated herring sperm 
DNA. Complimentary DNA probes for human RARa and RAR)9 were 
kind gifts of Ronald Evans (Salk Institute, San Diego, CA) and Magnus 
Ffahl (La Jolla Cancer Research Foundation, La Jolla, CA), 
respectively. The 618-base pair (bp) insert from the PSTl site of 
RARa (9) and the 615-bp insert from the EcoRI site of RAR^S (11) 
o Û 
were labeled to a specific radioactivity of 10 to 10 counts per 
min (CPM)/mg of DNA by a random hexamer primed oligolabeling kit 
(Pharmacia, Piscataway, NJ). Hybridization was carried out in fresh 
prehybridization buffer overnight at 42"C supplemented with RARa or 
RAR/8 probes (1 to 5 X 10^ CPM/ml) and carrier transfer RNA. 
Blots were washed twice in 2X SSPE, 0.1% SDS at room temperature for 10 
min, and twice in O.IX SSPE, 0.1% SDS at room temperature for 10 min 
each. For autoradiographs, XOMAT X-ray film (Eastman Kodak Co., 
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Rochester, NY) was exposed to the blot with intensifying screen for 1 
to 4 days. 
VDR assay 
For VDR assay, cells were grown to confluence. The media was then 
changed to that containing 1% PCS and the cells were treated with 
10"5 M of the indicated analog or vehicle for 16 h. Cells, harvested 
and sonicated in KID, and the supernatant of a high-speed 
centrifugation (230,000 X g) was labeled with a saturating dose of 
[^H]-1,25-(0H)2D3 with or without 100-fold excess 
1,25-(0H)2D3. Bound and free hormones were separated by 
hydroxyapatite chromatography. 
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RESULTS 
Sucrose density gradient analysis of hypertonic extracts of ROS 
17/2.8 cells showed a wide peak of specifically bound RA. To resolve 
this peak, cells were fractionated as described in Methods. This 
procedure resolved the single wide peak on sucrose gradients into two 
distinct specific RA-binding species. Figure la shows the results of 
sucrose gradient analysis of the cytosol for RA-binding activity. 
There is a single peak of specifically bound RA sedimenting at 
approximately 2.IS. Although ROS 17/2.8 cells had been reported (7) 
to have undetectable CRABP, this sedimentation coefficient is in 
agreement with published values for CRABP (14). For comparison, rat 
testis, a rich source of CRABP, was prepared in hypotonic buffer as 
above, and the labeled extract was analyzed on a sucrose gradient (Fig. 
lb). As with the ROS cytosol, a single peak of bound RA sedimented at 
ca. 2.IS. Further, as a check against any possible contamination by 
serum retinol binding protein (R6P), a 200-fold excess retinol was 
added to ROS cytosol during labeling. Excess retinol caused no loss of 
the 2.IS peak (data not shown). 
Analysis of the binding affinity for RA by ROS cytosolic protein is 
shown in Fig. 2. This binding component is saturable, and a Scatchard 
plot gives an estimate of - 51 ± 9.59 nH (mean ± S.E., n-3) with 
the sites/cell estimated to be 60,000. 
•J 
The [ H]-RA-labeled nuclear extracts also were analyzed by 
sucrose density gradient centrifugation. The profile (Fig. 3) showed a 
53 
peak of radioactivity sedimenting at ca. 3.3S. There was also a 
small peak of radioactivity near the top of the tube. The nature of 
this component is not clear. This is not, however, contamination by 
the cytosolic component. 
The binding affinity for RA by the 3.3S nuclear component is 
presented in Fig. 4. Scatchard analysis of the data yielded a linear 
plot with an estimate of the equilibrium dissociation constant of 
- 0.95 ± 0.05 nM (mean ± S.E., n-3). The ROS cells were estimated to 
contain 2,000 sites/cell. 
The affinity of selected retinoids for the nuclear receptor is 
presented in Table 1. The benzoic acid analogs Ro 13-7410 and SRI 
6409-40 compete effectively with RA for binding. Retinol exhibits an 
approximate 133-fold less affinity than RA for the nuclear receptor, 
and the analog SRI 5442-60 had essentially no binding. The binding 
affinity of each of these analogs to the nuclear receptor was compared 
with their ability to influence VDR concentration. With the exception 
of retinol (see below), there was a good correlation between binding 
affinity and increased concentration of VDR. 
As shown in Fig. 5, Northern blot analysis of poly (A)+ enriched 
RNA from ROS cells probed with RARa probe revealed two transcripts 
of ca. 2.6 and 3.5 kilobase (kb). The 2.6-kb transcript is found in 
greater abundance than the 3.5 kb transcript. The RAR)9 probe 
detected a single transcript of ca. 3.3-kb. 
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DISCUSSION 
Haussier et al. (7) observed no detectable CRABP in ROS 17/2.8 
cells. We assumed, therefore, that the responsiveness of this cell 
line to RA must be mediated via the nuclear receptor(s) for RA (8-12). 
Our initial experiments using hypertonic buffer to extract the cells 
showed a broad peak of specifically-bound radioactivity (on sucrose 
density gradient). This observation suggested two separate binding 
entities. To resolve them, we followed the procedure outlined in 
Methods. We found that there are indeed two separate RA-binding 
proteins. 
The specific RA-binding component present in hypotonic extracts has 
an apparent sedimentation coefficient of 2.1. Because this value is in 
close agreement with that previously determined for CRABP (7), we 
wanted to verify it against CRABP from rat testis (12, 15). The 
RA-binding component (CRABP) from a hypotonic extract of rat testes 
co-sediments with the RA-binding species from ROS cells. The binding 
of RA to the cytoplasmic RA-binding protein (CRABP) was not competed 
with a 200-fold excess of cold retinol. This specificity of binding 
and the apparent (see below) eliminates the possibility of 
contamination by RPB from serum that is either free or bound to 
putative surface receptors (16). 
The CRABP in ROS exhibits saturable binding of RA with an apparent 
Kj of 51 nM. This binding affinity, while relatively low, is within 
the range of values (4 to 65 nM) for CRABP from various tissues and 
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cell types (7, 14, 15). Given the high K^, it is possible that this 
protein may be GRÂBP-II, found in rat tissues, and reported to have an 
affinity for RA on the order of 15-fold less than that for CRABP-I 
(17). The copy number/cell of this CRÂBP is likewise low (6 X 10^ 
copies) compared with reports of that for other cell types (13.6 to 300 
X 10^ copies) (7). This, too, may suggest the presence of CRÂBP-II, 
as it was reported that the amount of CRABP-II obtained from rat 
tissues was 40% of that of CRABP-I (17). Whether this component is 
CRABP-II will require further study. It is clear, however, that ROS 
17/2.8 cells have a detectable RA-binding protein that conforms to the 
characteristics of CRABP. 
Sucrose density gradient analysis of the nuclear extract revealed a 
peak of specifically bound RA sedimenting at ca. 3.3S. This 
coefficient is in general agreement with that previously reported for 
RAR (4.OS) (18, 19), and is consistent with a protein of 
approximately 50,000 MW (20). The small peak (fraction 8) may be the 
recently reported 4500 MW retinoid-binding protein (21). 
This nuclear binding activity (RAR) is saturable, and the apparent 
- 0.95 nM is within the range of published values (0.5 to 1.5 nH) 
for RAR (20). This binding affinity is approximately 50 times higher 
than that exhibited by the cytosolic protein. The copies/cell of ca. 
2000 is, likewise, consistent with previous reports for RAR (22). This 
nuclear receptor for RA conforms to the classical steroid receptor 
characteristics of high affinity and low copy number. 
56 
The binding specificity of the nuclear receptor, for the analogs 
tested here, closely parallels data for RAR binding in HL-60 cells 
(22), chick embryo (23), and transfected CV-1 cells (9). The 
aroretinoids, Ro 13-7410 and SRI 6409-40, compete quite effectively 
with RA for binding to the nuclear receptor (Table 1). These two 
compounds bind RAR in HL-60 cells (22) and chick embryo (Ro 13-7410) 
(23, 24). The aroretinoid SRI 5442-60, previously shown not to bind 
HL-60 RAR (22), was an ineffective competitor. In HL-60 cells, retlnol 
does not compete with RA for binding to RAR (22). In CV-1 cells 
transfected with hybrid RAR, there was approximately a 166-fold 
increased requirement for retlnol to activate a reporter gene compared 
with RA (9). We report a ca. 133-fold difference in the affinity of 
RAR for RA and retlnol in ROS cell extracts. 
Evaluation of the binding specificity of the nuclear receptor and 
the ability of each of the analogs tested to regulate VDR indicates a 
close correlation between binding affinity and VDR regulation. 
Retinoic acid in these experiments increased VDR concentration 
2.71-fold. For the two aroretinoids for which the receptor shows 
relatively high affinity (Ro 13-7410 and SRI 6409-40), there is a good 
correlation between binding affinity and up-regulation of VDR. On the 
other hand, SRI 5442-40, which does not bind RAR, was unable to 
effectively regulate VDR concentration. These data are in close 
agreement with the affinity of these compounds for RAR and a measure of 
biological activity in HL-60 cells (22). Retlnol exhibits a high 
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inductive capacity that is not correlated to its affinity for the 
receptor. This may be the result of oxidation of retinol to retinoic 
acid in whole cell culture incubated for 18 h (25). 
The Northern analysis confirms that ROS cells express RAR. The two 
transcripts of 2.6 and 3.5 kb are consistent with other reports of the 
expression of RARa in rat tissues (24). This receptor form is 
ubiquitous, being expressed in nearly all tissues and responsive cell 
types examined (24, 26, 27). We have detected a single transcript of 
3.3 kb for RARy9 in ROS cells. Others have reported the presence of 
two transcripts (ca. 3.1 and 3.4 kb) in some tissue and cell types 
(24-26). In those cases reporting a single transcript, it is 
always the larger one (i.e., ca. 3.4 kb) that is consistent with the 
transcript size for RAR/3 in ROS 17/2.8 cells (23-25). 
Hybridization signal intensity for RARa and RAR/9 in ROS cells 
suggests that transcripts for RARa are relatively more abundant 
than those for RAR^. Whether this difference translates into a 
difference in RARa versus RARjS concentration is not 
ascertainable. 
We have demonstrated two distinct RA-binding proteins present in 
ROS 17/2.8 cells. What role these proteins play, either individually 
or in concert, in mediating RA-specific activity in ROS cells is not 
clear. The fact that CRABP is required in some contexts for the 
specific uptake of RA by nuclei (6) suggests that CRABP may serve to 
transport RA to the mostly nuclearly localized RAR (18, 22, 27). On 
the other hand, some compounds that have relatively high biological 
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activity do not bind CRABP with high affinity (20, 22, 28). Likewise, 
the aroretinoid SRI 6409-40, which has high biological activity and has 
a relatively low affinity for CRABP (29), was able to increase VDR 
concentration in ROS cells. Similarly, SRI 5442-60, which binds CRABP 
with high affinity (29), was an ineffective competitor for RAR binding 
and was unable to regulate VDR concentration. 
The RAR bind directly to DNA sequences and modulate gene 
transcription (30-35). A good correlation between analog affinity for 
RAR and increased VDR concentration indicates that this increase may be 
receptor-mediated. Inhibition of alkaline phosphatase activity in ROS 
cells by RA has been suggested to depend on gene transcription (5). It 
is possible, therefore, that these and other effects of RA in ROS 
cells, in particular, and bone, in general, are mediated all or at 
least in part by an RAR-dependent effect at the genomic level. 
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Figure 1. Sucrose density gradient analysis of bound RA in cytosol 
from ROS 17/2.8 and rat testes. Cytosols labeled with 
20 mM [ H]-RA ± 100-fold excess RA were layered onto 
5-20% sucrose gradients. After 18.5 h of centrifugation 
(438,000 X g), two drop fractions were collected and 
counted for radioactivity. The data is corrected for 
nonspecific binding 
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Saturation and gcatchard analysis of RA binding in 
ROS cytosol. The cytosol was labeled with the indicated 
concentration of [ H]-RA ± 100-fold excess RA. Bound 
and free RA were separated by hydroxyapatite. Data were 
plotted and then analyzed by the method of Scatchard 
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Figure 3. Sucrose density gradient analysis of bound RA in 
ROS 17/2.8 nuclear fraction. The nuclear fraction was 
labeled with 3 nM { H]-RA ± 100-fold excess RA and 
layered onto 5-20% sucrose gradients. After 18.5 h of 
centrifugation (438,000 x g), two drop fractions were 
collected and counted for radioactivity. The data is 
corrected for nonspecific binding 
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Figure 4. Saturation and Scatchard analysis of RA binding in 
ROS 17/2.8 nuclear fraction. The nuclear fraction was 
labeled with the indicated concentration of [ H]-RA ± 
100-fold excess RA. Bound and free EtA were separated by 
hydroxyapatite. Data were plotted and then analyzed by 
the method of Scatchard 
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Figure 5. Northern blot analysis of the expression of the genes for 
RARa and RAR^ in ROS 17/2.8 cells. Poly (A)+ RNA 
(20 /ig) isolated from ROS 17/2.8 cells were fraction­
ated, blotted and hybridized with [ P]-RARa and 
[ P]-RAR/3 as described 
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TABLE 1. Comparison of the ability of several retinoids to bind 
to ROS 17/2.8 RAR and to regulate VDR concentration 
Analog IC50 (nM) VDR 
Retinoic acid 0.75 2.71 
Retinol 100 2.12 
Ro 13-7410 2 2.28 
SRI 6409-40 10 1.68 
SRI 5442-60 >1,500 0.95 
Nuclear extract was incubated with 0.5 nM [ H]-RA in the 
presence of varying concentrations of unlabeled analog. 
[HJ-RA binding was assessed by hydroxyapatite chromatography. 
The IC5Q value is the concentration of analog which inhibits 
50% of the specific binding. VDR concentrations were measured in 
ROS cell extract after 18 h of treatment with 10" M analog. 
VDR is reported as the fold increase (fmole/mg protein) above 
untreated cells 
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SECTION III 
REGULATION OF RETINOIC ACID RECEPTORS IN RAT 
OSTEOSARCOMA 17/2.8 CELLS 
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INTRODUCTION 
Vitamin A and its analog, retinoic acid, have a wide array of 
effects on the proliferation and state of differentiation of many 
tissues, including cartilage and bone (1). Abnormal cartilage and bone 
development are associated with both toxicity and deficiency of vitamin 
A (2). There also have been suggested to be effects of vitamin A on 
the calcium regulatory parathyroid (PTH) and 1,25-dihydroxyvitamin Dg 
[1,25-(0H)2D3] hormones in rats (3). Cultured bone cells are re­
ported to be responsive to retinoic acid (RA). The rat osteogenic 
sarcoma cell line, UMR 106-06, shows a dose-dependent inhibition of 
growth (4) and an augmentation of PTH stimulation of cAMP-dependent 
protein kinase (5). In the rat osteoblast-like ROS 17/2.8 cells, RA 
increases the receptors for l,25-(0H)2Dg (VDR) (6), decreases alka­
line phosphatase (7) and attenuates PTH-stimulated cAMP concentrations 
(8). The effect of RA on VDR and alkaline phosphatase in ROS 17/2.8 
cells is, in part, a reflection of the changed steady state levels of 
their respective messenger RNAs (7, 9). 
Until recently, the molecular mechanism, through which RA effects 
are mediated, was unknown. With the demonstration of nuclear receptors 
(RARa, RAR/9, and RAR-y) for RA, similar to and members of 
the steroid receptor family of gene regulatory proteins, it became 
clear how many of the RA activities are mediated (10-14). The cloning 
of the genes for these nuclear receptors has facilitated the study of 
these receptors. RARa and RAR^ are found In most species and 
tissues, whereas RAR-y is found exclusively in skin and some 
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embryonic tissues (15), There is also a high degree of homology 
between these receptor sub-types, although there is a greater 
conservation for a sub-type across species than among sub-types within 
a species (14, 15). There, likewise, is a high degree of homology 
between RAR and the thyroid hormone receptor (TR). It, in fact, has 
been demonstrated that RAR can activate gene transcription through a 
thyroid hormone response element (TRE; 16) and that RAR and TR form 
heterodomers that bind TRE (17). 
The expression of the RAR/S is regulated homologously in most 
cell types investigated with induction as high as 30-fold (18-22). 
RARa expression, on the other hand, is relatively unaffected by RA 
(18, 19, 21-24). These findings are supported by the finding of a 
retinoic acid response element (RARE) in the 5'-flanking region of the 
RAR/9 gene to which RAR can bind and activate gene transcription 
(25-27). The 5'-flanking region of the RARa promoter, however, is 
unresponsive to RAR (28). I have demonstrated that the rat osteosar­
coma 17/2.8 cells express both RARa and RAR/9. Experiments were 
conducted to determine if the expression of these receptors is homolo­
gously regulated by RA and to determine if other hormones regulate 
RAR. In addition, I have investigated the interaction of thyroid 
hormone and RA in the regulation of VDR. 
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RESULTS 
To Investigate whether RÂ modulates the expression of its own recep­
tors, ROS 17/2.8 cells were grown in the presence of 10"% RA for 
several times, and RARa and RAR/9 mRNAs were analyzed by 
Northern blot. The concentration of mRNA for RAR/9 remained 
constant for 24 h post-treatment (Fig. 1 and 2). There was a rapid (2 
h) increase in RARa mRNA concentration after RA treatment (Fig. 1 
and 2). This increase reached 2-fold by 4 h and increased to as much 
as 5-fold by 24 h. 
RARa message was measured after 1,25-(OH)2D3-treatment (5 x 
10'^ M). RARa mRNA remained constant up to 8 h post-treatment 
(Fig. 3 and 4). A 1.4-fold increase was seen at 16 h with essentially 
no further increase by 24 h. There was no effect of 1,25-(ÔH)2D3 
on RAR/9 mRNA. 
It was shown previously that ROS 17/2.8 cells express both RAR and 
CRÂBP. To separate the predominantly cytoplasmic CRABP from the predom­
inantly nuclear RAR, differential fractionation of the cells, using 
hypo- and hyper-tonic buffers, was employed. Figure 5 illustrates the 
profile (control) of a sucrose density gradient analysis of the 
RA-binding component that was extracted from crude nuclear pellets. 
This component was previously identified as RAR and has a sedimentation 
coefficient of 3.3, which is distinct from that of CRABP (2.IS) in 
ROS cells. It is clear that CRABP is not evidentin this preparation 
(Fig. 5). 
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The effect of hormones on the RAR concentration of ROS cells was 
determined after 18-20 h of treatment (Table 1). The thyroid hormones 
(Tg, 10"* M; and T^, 10*® M) were without effect on RAR concen­
tration. Treatment with FTH (200 ng) decreased RAR approximately 50% 
from 145.8 ±12 to 75.8 ± 10 fmol/mg protein. Twenty hours of 
1,25-(0H)2D3 (5 X 10"* M) treatment lead to a greater than 50% 
decrease In RAR concentration. The PTH- and 1,25-(OH)2D3-mediated 
decreases In RAR are Illustrated further by sucrose density gradient 
analysis (Fig. 5a and b). Scatchard analysis (data not shown) support 
a loss of binding sites with no change in affinity for RA with 
1,25-(0H)2D3 or PTH treatment. 
The kinetics of l,25-(OH)2D3 effect on RAR were analyzed (Fig. 
6). The RAR concentrations remained constant up to 4 h 
post-treatment. At 8 h, receptor concentrations began to decline, 
leading to a 45% decrease at 24 h. 
The effect of the interaction of RA and thyroid hormones on VDR was 
determined (Table 1). RA (10"^ M) treatment for 20 h lead to a large 
increase in VDR from 34 ± 2.5 to 258 ± 13 fmol/mg protein. Both Tg 
(10"* M) and T^ (10"® M) treatment caused a slight increase in 
VDR concentration. When cells were treated with both T3 and RA for 
20 h, there was an attenuation of the RA-medlatetd Increase in VDR 
concentration. Because 1,25-(0H)2D2 (5 X 10"* M) homologously 
up-regulates VDR (Table 1), an interaction between l,25-(OH)2 and 
Tg was Investigated. When cells were treated with both 
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1,25-(OH)2^3 and T3, VDR concentration was the same as for 
l,25-(0H)2D3-treated cells (359 ± 5 and 374 ± 12 fmol/mg protein, 
respectively). Lack of apparent Interaction of l,25-(OH)2D3 and 
T3 on VDR concentration Is comparable to a similar lack of combined 
effect of these hormones on RAR (Table 1). 
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DISCUSSION 
I have shown, in contrast to a number of previous reports of 
(18-22) regulation of RAR^ mRNA by RA, that ROS 17/2.8 cells do not 
respond to RA by increasing RAR^ mRNA. The murine S91 melanoma 
cells, in which RAR/9 is not expressed constitutively, respond to RA 
rapidly (2 to 4 h) to induce RAR)9 mRNA (18, 21). Similarly, terato-
carcinoma F9 cells (19, 20) and the hepatoma PLC/PRF/5 and HEFG2 cells 
(22) rapidly increase RAR/9 mRNA 10- to 50-fold in response to RA. 
The ROS 17/2.8 cells show a 1.5-fold increase by 2 h, which declines to 
control concentrate by 8 h and shows a tendency toward a slight de­
crease by 24 h. The lack of response to RA is most likely a 
cell-specific difference in regulation of RAR/9 gene expression. It 
has been demonstrated that the promoter region of the human (25, 26) 
and murine (27) RAR/9 gene contains a retinoic acid response element 
(RARE). Although the rat RAR/9 gene promoter region has not been 
characterized, it has been shown that rat-derived Ito cells respond to 
RA by increasing RAR/9 mRNA (34). A cell-specific difference is 
supported further by the finding that RAR binding to specific 
cis-elements is dependent upon the presence of cell-type specific 
nuclear factors (35). 
Retinoic acid treatment did increase mRNA for RARa. There was 
a fairly rapid 2-fold increase (2 to 4 h) that peaked at as much as 
5-fold at 24 h. These results are similar to the 7- and 8-fold 
increase in RARa mRNA with RA treatment of the mutant RAC6S and P19 
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embryonal carcinoma cells, respectively (23). The RA-medlated 
induction of RARa message in these cells was more rapid, peaking at 
2 to 12 h. In general, the RARa gene is not regulated by ElA, 
whereas RAR)9 gene is. Therefore, it is plausible that differential 
induction of RAR genes, in various tissues, mediates differential 
retinoid-induced gene expression. 
Although ROS cells express both CRABP and RAR, the extraction proce­
dure herein utilized is adequate to separate these two RA-blndlng pro­
teins. It thus is possible to measure changes in apparent RAR concen­
tration as an effect of treatment. The calcium regulatory proteins, 
PTH and 1,25-(OH)2D3, down-regulate RAR by 50%. The fact that this 
loss is a direct effect on RAR is demonstrated by the results of su­
crose density gradient centrifugation (Fig. 5). The apparent loss of 
RA-binding sites is from the 3.3S species that I have previously 
Identified as RAR. Surprisingly, the effect of l,25-(OH)2D3 on RAR 
concentration is not a reflection of l,25-(OH)2D3 effect on 
RARa message concentrations. Although an effect of 
l,25-(OH)2D3 on RAR^ mRNA cannot be ruled out, it is probable 
that 1,25-(0H)2D3 effects are post-transcriptional. 
Whether this effect is VDR-mediated is not clear. It has been 
demonstrated recently that 1,25-(011)203 can increase intracellular 
calcium. Inositol triphosphate, and diacylglycerol in ROS 17/2.8 cells 
(36). It, therefore, is possible that the similar effects of 
l,25-(OH)2D3 and PTH are mediated by the same pathway. Although 
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PTH is reported to stimulate both the cAMP- and [Ca^*^]independent 
pathways-in ROS 17/2.8 cells (37), it has been shown that a cAMP analog 
was unable to stimulate RAR gene expression in F9 cells (20). 
RAR and thyroid hormone receptors (TR) are reported to bind to the 
same gene control elements independently (16) and as heterodimers 
(17). It, likewise, has been demonstrated that ligand mediated gene 
regulation by one of these receptors can be altered in the presence of 
the other unliganded receptor (17, 38, 39). Because ROS 17/2.8 cells 
are reported to express TR (40), we investigated whether RA and Tg 
interact to regulate VDR. RA is known to up-regulate VDR in ROS cells 
(6, 8, 9) and there was a substantial increase in these experiments. 
Essentially Tg and had no effect on VDR concentration. When ROS 
cells were incubated with RA in the presence of there was a 
marked inhibition of the RA-mediated response. This effect of T3 was 
specific for the RA-mediated up-regulation because the addition of Tg 
with 1,25-(0H)2D3 had no effect on homologous up-regulation of 
VDR. This apparent lack of T3/1,25-(011)203 interaction is 
demonstrated further by the fact that Tg had no effect on 
1,25-(0H)2D3 down-regulation of RAR. It is tempting to speculate 
on the mechanism of RA/T3 effect. It is possible that a competition 
by liganded receptors exists for the same cis-element. T3-TR may 
bind the same control element as RA-RAR and thereby block 
RA-RAR-mediated effects. This hypothesis is supported somewhat by the 
slight, but consistent, Increase in VDR concentration with T3 or T^ 
treatment. 
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Based on the data presented, RÂ autoregulates the concentration of 
mRNA for-RARa but not RARyS. The level at which the regulation 
occurs will need to be determined. This finding does suggest that RA 
effects In ROS may be controlled by varying RARa concentrations. 
It is possible that RA regulation of RARa is secondary, given the 
length of time for mRNA Increase and the fact that no RARE has been 
identified in the 5'-flanking region of RARa (28). The results of 
treatment of ROS cells with PTH and l,25-(OH)2D3 is the first demon­
stration of changes in RAR concentration. It is important to note the 
effects on both message and protein since an apparent lack of effect on 
mRNA does not exclude possible translational or post-translational 
effects. (This clearly is the case for l,25-(OH)2D3 treatment.) 
Finally, I report an intriguing effect of RA and Tg on VDR 
concentration. It is not at all unlikely that RAR and TR Interact in a 
manner similar to those previously reported (16, 17, 38, 39). 
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MATERIALS AND METHODS 
General 
Synthetic 1,25-(011)203 was a gift from Milan P. Uskokovlc 
(Hoffmann-La Roche, Nutley, NJ). l,25-Dlhydroxy[26,27-3H]vltamln 
D3 (85 Cl/mmol) [l,25-(OH)2[^H]D3] was prepared as previously 
described (29). All trans-retlnolc, L-thyroxlne (T^) and 
3,3',5-trllodo-L-thyronine (T3) were purchased from Sigma Chemical 
Company (St. Louis, MO). The AGI-IXIO (chloride form) affinity resin 
was from Bio-Rad (Richmond, CA). Pure synthetic bovine PTH (1-34) was 
obtained from Peninsula Laboratories (San Carlos, CA). The vehicle for 
PTH was 1 mM HCl, 0.15 M NaCl, and 2% cysteine. All trans-retlnolc 
acid [11,12-^H] (50 Cl/mmol) was purchased from Dupont/NEN 
(Wilmington, DE). Retinoic acid and 1,25-(0H)2D3 were prepared in 
ethanol and quantitated by using molar extinction coefficients of 
45,000 M'lcm'l at 351 nm and 18,200 M'^Cm"^ at 265 mM, 
respectively. Antibiotics and fetal calf serum (PCS) and cell culture 
medium (RPMI 1640) were purchased from Grand Island Biological Company 
(Grand Island, NY). 
Cell culture 
Rat osteosarcoma 17/2.8 cells (ROS 17/2.8 cells) were grown in RPMI 
1640 supplemented with 10% PCS and antibiotics. Cells were grown to 
confluence (7 to 8 days) with feeding every third day at incubation 
conditions of 37"C, with an atmosphere of 5% CO2 and humidified air. 
At the start of each experiment, media was changed to RPMI 1640 
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containing 1% PCS. In those experiments using T3 and T^, the cells 
were grown as above except that at the first media change the cells 
were fed fresh RFMI 1640 with 10% thyroid hormone-depleted calf serum 
[10% TH(-) media]. Calf serum was depleted of thyroid hormones as 
described (30). At the start of each of the Tg or experiments, 
media was replaced by RFMI containing 1% TH(-) PCS. Cells were treated 
with the indicated hormones or vehicle ethanol never exceeded 0.1% in 
any flask. 
RAR and VDR assay 
For RAR assay, treated cells were harvested at the indicated times 
by trypsin-EDTA. Cells were washed twice in Hank's balanced salt solu­
tion (without Ca"*"*" and Mg"*^) at 4®C. The cell pellet was sonicated 
at 2 X 10^ cells/mL in hypotonic TD buffer (10 mM Tris, pH 7.4, 5 mM 
dlthiothreitol) using a Branson Sonifler. This extract was centrifuged 
for 20 min at 1000 X g. The resulting crude nuclear pellet was washed 
once in TD. The nuclear pellet was then homogenized In one-half origi­
nal volume of hypertonic buffer KTD (TD plus 500 mM KCl). This homoge-
nate was centrifuged at 230,000 X g for 20 min using a Beckman Ti 70.1 
rotor and a L8-80M ultracentrifuge. Por VDR assay, harvested cells 
were sonicated in KTD and the resulting homogenate was centrifuged at 
230,000 X g for 20 min. Triplicate allquots (500 mL) were Incubated 
with either 2 nM [^H]-RA or 8 nM l,25-(OH)2- [^HjDj with or 
without a 100-fold excess of RA or 1,25-(0H)2D2, respectively, for 
3 h at 4"C. Bound and free hormones were separated by using hydroxyapa-
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tlte chromatography. All assays were corrected for nonspecific binding 
and are presented as femtomoles per mg protein. Protein was determined 
by the Bradford method using a bovine serum albumin standard (31). 
Sucrose density gradient centrifugation 
A 200-mL aliquot of radiolabeled extract was layered onto 4 mL of a 
continuous 5 to 20% (w/v) KTD sucrose gradient. The gradients were 
centrifuged at 438,000 X g for 18.5 h in a Beckman SW60Ti rotor and a 
Beckman L8-80M ultracentrifuge. Two-drop fractions were collected and 
counted for radioactivity in Beckman Ready SOLV HP using a Beckman 
LS-7800 liquid scintillation counter. All assays are corrected for 
nonspecific binding and are presented as specifically bound [^H]-RA. 
[^^C]-Ovalbumin (3.6S) and [^^C]-gamma globulin (6.8S) were 
included as internal markers. 
Northern blot analysis 
Total RNA was extracted from cells as described (32) and enriched 
for poly (A)+ RNA on an oligo-dT-cellulose column. Ten to 20 fig of 
poly (A)+ enriched RNA was fractionated under denaturing conditions on 
a 1% agarose/5% formaldehyde gel and transferred to Optibind nitrocellu­
lose (Schleicher and Schuell, Keene, NH). The RNA was cross-linked to 
the membrane with UV light. Membranes were prehybridized for 1 h at 
42*C in 50% formamide, 5X Denhardt's solution, 0.5% sodium dodecyl 
sulfate (SDS), 5X SSPE (SSPE - 0.18M NaCl, 10 mM NaPOj, pH 7.7, 1 mM 
EDTA) and 50 pg/mL sonicated herring sperm ONA. Complementary DNA 
probes for human RARa and RAR^ were kindly provided by Dr. 
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Ronald Evans (Salk Institute, San Diego, CÂ) and Dr. Magnus Ffahl (La 
Jolla Cancer Research Foundation, La Jolla, CA), respectively, The 
618-bp (base pair) Insert from the PSTI site of RARa (10), the 
615-bp Insert from the EcoRI site of RARj9 (13), and the 2.1 kbp 
Insert from the Hlndlll site of the chick ^ -actln gene (33) were 
Q Q 
labeled to a specific radioactivity of 10 to 10 counts per mln 
(cpm)//ig of DNA by using Pharmacia ollgolabellng (Pharmacia, Plscat-
away, NJ). Hybridization was carried out (overnight at 42'C) In fresh 
prehybrldlzatlon buffer supplemented with the appropriate probes (1-5 X 
10^ cpm/mL) and carrier transfer RNA. Blots were washed twice In 2X 
SSPE, 0.1% SDS at room temperature for 10 mln and twice In 0.1% SSPE, . 
0.1% SDS at room temperature for 10 mln. For autoradlographs, XOMAT 
X-ray film (Eastman Kodak Co., Rochester, NY) was exposed to the blots 
with Intensifying screens for 4 to 96 h. Filters also were counted and 
Imaged; bands were quantltated by using an Ambls Radloanalytlc Imaging 
System (Ambls System, San Diego, CA). 
84 
REFERENCES 
1. Roberts Âfi and Sporn MB 1984 Cellular biology and biochemistry of 
the retinoids. In: Sporn MB, Roberts AB and Goodman DS (eds), The 
Retinoids, Vol. 2 Academic Press, Orlando, FL, p 209 
2. Navia JM and Harris SS 1980 Vitamin A influence on calcium 
metabolism and calcification. Ann NY Acad Sci 355:45 
3. Frankel XL, Seshadri MS, McDowall DB and Cornick CJ 1986 
Hypervitaminosis A and calcium-regulating hormones in the rat. J 
Nutr 116:578 
4. Ng KW, Livesey SA, Collier F, Gummes PR and Martin TJ 1985 
Effects of retinoids on the growth, ultrastructure, and 
cytoskeletal structures of malignant rat osteoblasts. Cancer Res 
45:5106 
5. Livesey SA, Ng KW, Collier OR, Kubota M, Steiner AL, and Martin TJ 
1985 Effect of retinoic acid on cellular content and human 
parathyroid hormone activation of cyclic adenosine 3':5'-monophos­
phate - dependent protein kinase isoenzymes in clonal rat osteogenic 
sarcoma cells. Cancer Res 45:5734 
6. Petkovich PM, Heerche JNM, Tinker DO and Jones G 1984 Retinoic 
acid stimulates 1,25-dihydroxyvitamin D3 binding in rat 
osteosarcoma cells. J Biol Chem 259:8274 
85 
7. Imal Y, Rodan SG and Rodan GA 1988 Effects of retlnolc acid on 
alkaline phosphatase messenger ribonucleic acid, colecholamine 
receptors, and G proteins in ROS 17/2.8 cells. Endocrinology 
122:456 
8. Grigoriades HE, Fetkovich FM, Rosenthal EE and Heersche JNM 1986 
Modulation of retinoic acid of 1,25-dihydroxyvitamin D3 effects 
on alkaline phosphatase activity and parathyroid hormone 
responsiveness in an osteoblast-like osteosarcoma cell line. 
Endocrinology 119:932 
9. Reinhardt TA and Horst RL 1990 Farathyroid hormone down-regulates 
1,25-dihydroxyvitamin D receptors (VDR) and VDR messenger 
ribonucleic acid in vitro and blocks homologous up-regulation of 
VDR in vivo. Endocrinology 127:942 
10. Giguere V, Ong ES, Segui P and Evans RM 1982 Identification of a 
receptor for the morphogen retinoic acid. Nature 330:624 
11. Fetkovich M, Brand NJ, Krust A and Chambon F 1987 A human 
retinoic acid receptor which belongs to the family of nuclear 
receptors. Nature 330:444 
12. Brand N, Fetkovich M, Krust A, Chambon F, de Thé H, Marchio A, 
Tiollais F and Dejean A 1988 Identification of a second human 
retinoic acid receptor. Nature 332:850 
13. Benbrook D, Lenhardt E and Ffahl M 1988 A new retinoic acid 
receptor identified from a hepatocellular carcinoma. Nature 
333:669 
86 
14. Krust A, Kastner P, Petkovich M, Zelent A and Chambon P 1989 A 
third human retinoic acid receptor, hRAR-y. Proc Natl Acad Sci 
86:5310 
15. Zelent A, Krust A, Petkovich H, Kastner P and Chambon P 1989 
Cloning of murine a and retinoic acid receptors and a 
novel receptor y predominantly expressed in skin. Nature 
339:714 
16. Umerono K, Giguere V, Glass CK, Rosenfeld MG and Evans RM 1988 
Retinoic acid and thyroid hormone induce gene expression through a 
common element. Nature 336:262 
17. Glass CK, Lipkin SM, Devony OV and Rosenfeld MG 1989 Positive and 
negative regulation of gene transcription by a retinoic 
acid-thyroid hormone receptor heterodimer. Cell 59:697 
18. Clifford JL, Petkovich M, Chambon P and Lotan R 1990 Modulation 
of retinoids of mRNA levels for nuclear retinoic acid receptors in 
murine melanoma cells. Mol Endocrinol 4:1546 
19. Hu L and Gudas U 1990 Cyclic AMP analogs and retinoic acid 
influence the expression of retinoic acid receptor a, and 
7 mRNA's in F9 teratocarcinoma cells. Mol Cell Biol 10:391 
20. Martin CA, Ziegler LM and Napoli JL 1990 Retinoic acid, 
dibutryl-cAMP and differentiation affect the expression of the 
retinoic acid receptors in F9 cells. Proc Natl Acad Sci 87:4804 
21. Redfern CPF, Daly A, Latham JAE and Todd C 1990 The biological 
' activity of retinoids in melanoma cells. FEES Lett 273:19 
87 
22. de Thé H, Marchln A, Tiollair P and Dejean A 1989 Differential 
expression and ligand regulation of the retinoic acid receptor 
a and genes. EHBO J 8:429 
23. Song S and Siu C-H 1989 Retinoic acid regulation of the 
expression of retinoic acid receptors in wild type and mutant 
embryonal carcinoma cells. FEES Lett 256:510 
24. Gallager RE, Said F, Pua I, Fapenhausen PR, Paietta E and Weirnik 
PH 1989 Expression of retinoic acid receptor-a mRNA in human 
leukemia cells with variable responsiveness to retinoic acid. 
Leukemia 3:789 
25. de Thé H, Vivanco-Ruiz MDM, Trollais P, Stunnenberg H and Dejean A 
1990 Identification of a retinoic acid responsive element in the 
retinoic acid receptor p gene. Nature 343:177 
26. Hoffman B, Lehmann JM, Zhang X-K, Hermann T 1990 A retinoic acid 
receptor-specific element controls the retinoic acid receptor-^ 
promoter. Mol Endocrinol 4:1727 
27. Sucov HM, Murakami KK and Evans RM 1990 Characterization of an 
autoregulated response element in the mouse retinoic acid receptor 
type p gene. Proc Natl Acad Sci 87:5392 
28. Brand NJ, Petkovich M and Chambon P 1990 Characterization of a 
functional promoter for the human retinoic acid receptor-alpha 
(hRARa). Nuc Acid Res 18:6799 
29. Reinhardt TA and Horst RL 1989 Self-inducter of 1,25-dihydroxy-
vitamin Dg metabolism limits receptor occupancy and target tissue 
responsiveness. J Biol Chem 264:15917 
88 
30. Samuels HH, Stanley F and Casanova J 1979 Depletion of L-3,5,5'-
trlllllodothyronlne and L-thyroxine in euthyroid calf serum for us 
in cell culture studies of the action of thyroid hormone. 
Endocrinology 105:80 
31. Bradford MM 1976 A rapid and sensitive method for the 
quantitation of microgram quantities of protein utilizing the 
principle of protein-dye binding. Anal Biochem 72:248 
32. Chomczynski P and Sacchi N 1987 Single-step method of RNA 
isolation by acid guanidinium thiocyanate-phenol-chloroform 
extraction. Anal Biochem 162:156 
33. Cleveland DW, Lopata MA, Macdonald RJ, Cowan NJ, Rutter WJ and 
Kirschmer MW 1980 Number and evolutionary conservation of a-
and ^-tubulin and cytoplasmic and 5-action genes using 
specific cloned cDNA probes. Cell 20:95 
34. Weiner FR, Shah A, Blaner W and Geerto A 1990 Nuclear retinoic 
acid receptor expression in Ito cells. Hepatology 12:922 
35. Glass CK, Devany OV and Rosenfeld MG 1990 Multiple cell 
type-specific proteins differentially regulate target sequence 
recognition by the a retinoic acid receptor. Cell 63:729 
36. Civitelli R, Kim YS, Gumsten SL, Fujimori A, Huskey M, Avioli LV 
and Hruska KA 1990 Nongenomic activation of the calcium-message 
system by vitamin D metabolites in osteoblast-like cells. 
Endocrinology 127:2253 
89 
37. Bidwell JP, Fryer MJ, Finek AF, Donahue HJ and Heath H 1991 
Desensltlzatlon of rat osteoblast-like cells (ROS 17/2.8) to 
parathyroid hormone uncouples the adenosine 35'-monophosphate and 
cytosolic ionized calcium response limbs. Endocrinology 128:1021 
38. Graupner G, Wills KN, Tzukeman M, Zhang X-K and Ffahl M 1986 Dual 
regulatory role for thyroid-hormone receptors allows control of 
retinoic acid activity. Nature 340:653 
39. Hudson LG, Santon JB, Glass CK and Gill GN 1990 Ligand-activated 
thyroid hormone and retinoic acid receptors inhibit growth factor 
receptor promoter expression. Cell 62:1165 
40. Sato K, Han DC, Fujii Y, Tsushima T and Shizume K 1987 Thyroid 
hormone stimulates alkaline phosphatase activity in cultured rat 
osteoblastic cells (ROS 17/2.8) through 3,5,3'-triiodo-L-thyronine 
nuclear receptors. Endocrinology 120:1873 
""làlili 
Mctin ###### 
R A R P  
Time (h) 
Figure 1. Kinetics of RA effect on RARa and RAR/9 mRNA 
expression. ROS 17/2.8 cells were treated with 
10" M RA for the indicated times. Poly (A)+ RNA 
(20 /ig/lane) was size-fractionated and blotted. The 
blot was hybridized with [ P]-RARa. The blot 
was stripped and hybridized with [ P]-y9-actin 
followed by [ P] -RAR/9 
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Figure 2. Quantitative representation of the kinetics of RARa 
and RAR/9 mRNA modulation by RA. The quantitation of 
RA effect was by direct proportional counting of the blots 
in Fig. 1 using Ambis Radioanalytic Imaging System. The 
data were normalized for loading differences using the 
^-actin probe * p < .05; p < .01 
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Figure 3.  Kinetics of l ,25-(0H)2Dg effects on RARQ and 
RARjS mRNA exgression. ROS 17/2.8 cells were treated 
with 5 X 10" M 1,25-(0H)2D2 for the indicated 
times. Poly (A)+ RNA (20 /ig/lane) was size-fraction­
ated and blotted. The blot was hybridized with [ P] 
R^a. The blot was stripped and hybridized with 
[32p]-p-actin followed by [^^FJ-RAR/S 
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Figure 4. Quantitative representation of the kinetics of RARa 
and RÂR/9 modulation by l,25-(0H)2Dg. The quanti­
tation of 1,25-(0H)2D3 effect was by direct propor­
tional counting of the blots in Fig. 1 using Ambls Radio-
analytic Imaging System. The data were normalized for 
loading differences using the ^-actln probe 
*p < .1 
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Figure 5. Sucrose density gradient analysis of RAR from ROS 17/2.8 
cells. ROS cells were treated with l,25-(OH)2Do 
(5 X 10" M) or PTH (200 ng) for 24 h. A cellular 
extract was prepared as described in Methods and labeled 
with 2 nM [ H]-RA ± 100-fold excess RA. A 0.25 mL 
aliquot was centrifuged on a 5-20% (w/v) sucrose gradient 
for 18.5 h at 438,000 x g. Two drop fractions were 
collected and counted for radioactivity. Data are correct 
for nonspecific binding. [C]-Ovalbumin (0) and 
[C]-gamma globulin (G) were used as markers 
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Figure 6. Kinetics of l,25-(OH)2D3 effect on ElAR concentration. 
ROS 17/2.8 cells were treated with l,25-(OH)2Do 
(5 X 10' M) for the Indicated times. A cellular 
extract was prepared and labeled as described in Fig. 5. 
Bound and free [^H]-RA were separated by hydroxyapatlte. 
Data are corrected for nonspecific blading and normalized 
for protein concentration p < .1; p < .05 
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TABLE 1. Effect of hormone on RAR and VDR concentration of 
ROS 17/2.8 cells 
Treatments RAR VDR 
fmol/mg protein 
Control 146 ± 12 34 ± 2 
1,25-(0H)D3 69 ± 7® 374 ± 12® 
PTH 78 ± 10^ -
T3 140 ± 8 50 ± 3^ 
T4 132 ± 11 52 ± 6^ 
1,25-(0H) 2  +  T3 78 ± 8® 359 ± 5® 
RA - 258 ± 13® 
RA + T3 - 124 ± 16° 
ROS 17/2.8 cells were treated with l,25-(OH)2D3 (5 x 10'* M), 
PTH (200 ng), T3 (lO'B M), T4 (lO'* M), RA (10"^ M) or vehicle 
for 20 h. ROS cell extracts for RAR and VDR assay were prepared as 
described in Methods. The extracts were labeled with 2 nM [ H]-RA ± 
lOO-fold excess or 2 nM [ H]-l,25-(OH)2D3 ± 100-fold excess for 
RA and VDR, respectively. Receptor concentration was determined as 
described in Fig. 6. 
^ p < .01 (compared with control) 
^ p < .1 (compared with control) 
° p < .01 (compared with RA) 
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SUMMARY AND DISCUSSION 
The effects of the active hormonal form of vitamin D, 
1,2S-dlhydroxyvltamln D, are mediated by Its cognate receptor. This 
receptor belongs to the family of nuclear receptors that bind to 
discrete DNA sequences and modulate gene expression. In Section I of 
this dissertation, the effect of the metal cation chelator, 
1,10-phenanthrollne, on the DNA-blnding activity of the l,25-(OH)2D 
receptor was investigated. A dose-dependent decrease In receptor 
DNA-blnding was evident with Increasing chelator concentration. This 
binding was a chelator-speclflc action because EDTA treatment exhibited 
a similar effect and the nonchelating analog, 1,7-phenanthroline, did 
not inhibit binding of the cations tested (Ba^*, Ca^*, Cd^^, 
Mg^*, Zn^"^). Only Cd^* and Zn^* were effective in blocking the 
chelator-medlated loss of DNA-blnding activity of the receptor. None 
of the cations, however, were effective in reversing the loss of 
binding if the receptor was preincubated with 1,10-phenanthrollne. If 
Cd^* or Zn^* were added to receptor preparations that had been 
dlalyzed to remove the chelator, a substantial recovery in DNA-blnding 
activity was observed. Analysis of chelator-treated receptor by 
high-performance size exclusion chromatography suggests the chelator 
caused the formation of aggregates and possibly cation-devoid 
aporeceptor. This analysis further suggests that addition of cation 
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after dialysis reconstitutes the aporeceptor, thereby recovering 
DNA-blndlng activity. 
In Section II, the presence of the nuclear retlnolc acid receptor 
and the cellular retlnolc acid binding protein (In the ROS 17/2.8 
cells) Is demonstrated. The finding of the cellular binding protein 
was a surprise because It was reported by others not to be expressed by 
ROS cells. The retlnolc binding protein recovered from a hypotonic 
extraction of cells has a sedimentation coefficient the same as that of 
cellular retlnolc acid binding protein extracted from rat testes 
(2.IS). This binding protein exhibited saturable binding of retlnolc 
acid and has a equilibrium dissociation constant (51 nM) within the 
range of that for cellular retlnolc acid binding protein derived from 
other sources. ROS cells also express the nuclear receptor for 
retlnolc acid. This protein, likewise, exhibits saturable binding of 
retlnolc acid with - 0.95 nM. The binding affinity by the 
sedimentation coefficient of 33 demonstrated that this protein is 
distinct from the cellular retlnolc acid binding protein. There was a 
close correlation found between the ability of various analogs to bind 
to this receptor and the analogs ability to up-regulate 
1,25-(0H)2D2 receptor concentration In ROS cells. By using 
Northern blot analysis with cDNA probes for retlnolc acid receptor 
a and /9, it was demonstrated that ROS cells express mRNA for 
these two forms of the retlnolc acid receptor. 
In Section III, the regulation of expression of retlnolc acid 
receptors by retlnolc acid and other hormones Is demonstrated. 
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Retlnolc acid was essentially without effect on mRNA concentration of 
RAR^. Retlnolc acid treatment Induced a rapid (2-4 h) Increase In 
RARa mRNA. This Increase was as high as 5-fold by 24 h post-
treatment. Treatment of ROS cells with l,25-(OH)2D3 for 24 h was 
without effect on retlnolc acid receptor mRNA concentration. Both 
1,25-(0H)2D3 and parathyroid hormone decreased retlnolc acid 
receptor number by 50% after 20 h. This apparent loss of retlnolc acid 
receptor binding sites was demonstrated by sucrose density gradient 
centrlfugatlon. The effect of l,25-(OH2D3 may be a nonreceptor-
medlated translatlonal or post-translatlonal effect. This decrease In 
receptor concentration Is the first demonstration of a change of any 
kind In retlnolc acid receptor concentration. An effect of the 
combination of retlnolc acid and thyroid hormone on l,25-(OH)2D3 
receptor concentration was demonstrated. This Interaction Is unique to 
these two hormones because the combination of l,25-(OH)2D3 and 
thyroid hormone failed to exhibit a similar effect on l,25-(OH)2D3 
receptor or retlnolc acid receptor concentrations. It Is speculated 
that this effect Is a function of competition for a DNA binding site by 
the receptors for retlnolc acid and thyroid hormone. 
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